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APOE AS A METABOLIC REGULATOR IN HUMANS, MICE, AND ASTROCYTES 
 
Altered metabolic pathways appear to play central roles in the pathophysiology of 
late-onset Alzheimer’s disease (AD). Carrier status of the E4 allele of the APOE gene is 
the strongest genetic risk factor for late-onset AD, and increasing evidence suggests that 
E4 carriers may be at an increased risk for neurodegeneration based on inherent metabolic 
impairments. A new appreciation is forming for the role of APOE in cerebral metabolism, 
and how nutritional factors may impact this role. In chapter 1, the literature on nutritional 
interventions in E4 carriers aimed at mitigating disease risk is reviewed. Studies 
investigating the mechanism by which E4 increases disease risk have focused primarily on 
the association of E4 with the neuropathological hallmarks. While these studies have aided 
in our understanding of the role of E4 in late-disease pathology, investigating metabolic 
signatures of E4 carriers who have not yet developed neuropathology gives insight into the 
potential earlier mechanisms of E4 as a risk factor for AD. For example, an early and 
consistent biological hallmark of AD is cerebral glucose hypometabolism as observed by 
fluorodeoxyglucose positron emission tomography (FDG-PET). Interestingly, E4 carriers 
also display an AD-like pattern of decreased glucose metabolism by FDG-PET far before 
clinical symptomology. Since glucose hypometabolism occurs early in AD and early in E4 
carriers, it may represent a critical prodromal phase of AD. Beyond this brain imaging 
finding, it is unclear if APOE has any other discernable metabolic effects in cognitively 
unimpaired young people. In chapter 2 we bridge this knowledge gap in the field. We 
utilized indirect calorimetry (IC) as a method for assessing metabolism in young and 
middle aged volunteers with and without the E4 allele. While IC is commonly used in 
clinical settings to assess nutritional status, it has never been used to assess risk for 
cognitive decline. Thus, repurposing IC to study the metabolic effects of an AD risk factor 
such as E4 represents a simple, cost-effective, and innovative new approach. We found that 
young female E4 carriers show a lower resting energy expenditure compared to non-
carriers. We also tested how E4 carriage affects response to a glucose challenge by 
administering a glucose rich beverage in conjunction with IC measurements and plasma 
metabolomics. We found that female E4 carriers were unable to increase oxygen 
consumption relative to non-carriers, reflecting an impairment in glucose oxidation. 
Additionally, the plasma metabolome of E4 carriers showed increased lactate and an 
overall metabolic profile consistent with aerobic glycolysis. We translated these findings 
to mice expressing the human alleles of APOE. We found that E4 mice on a normal chow 
diet have lower energy expenditure than E3 mice, a difference further exacerbated by high 
carbohydrate diet feeding. Stable isotope tracing in mice whole brains and astrocytes 
     
 
implicate increased utilization of aerobic glycolysis as a mechanism for altered glucose 
handling in E4 carriers. Another pathological feature of the Alzheimer’s brain is glial lipid 
accumulation. The mechanism for this is largely unknown. In chapter 3, the literature 
pertaining to lipid droplets (LD) in the brain is reviewed. We show that LDs are much more 
than simple fat depots, playing critical roles in metabolism, inflammation, and various 
neurodegenerative diseases. In chapter 4, the effect of the E4 allele on astrocyte LD 
accumulation and turnover is assessed. Using an in vitro model of APOE we probed the 
storage and oxidation capacity of fatty acids in E3 and E4 astrocytes. We observed that E4 
astrocytes exhibit greater storage of fatty acids as LDs under control and lipid loaded 
conditions compared to E3 astrocytes. Furthermore, we found that E4 astrocytes rely on 
these LDs as a source of fuel for oxidation. Therefore, APOE appears to regulate whole 
body energy expenditure, cerebral glucose oxidation, astrocyte LD metabolism, and risk 
for a host of metabolic diseases. In chapter 5, the evolutionary history of APOE is presented 
to posit a hypothesis for why E4 may be disadvantageous in modern times compared to its 
prior advantages in the pre-historic era. These results point toward a larger role for APOE 
in the regulation of metabolism than previously understood and advocates for alternative 
nutritional approaches including calorie reduction and intermittent fasting as plausible 
interventions to mitigate disease risk in E4 carriers.  
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CHAPTER 1. EFFECTS OF APOE IN NUTRITIONAL METABOLISM IN 
DEMENTIA 
[This chapter consists of material adapted from a published manuscript: Farmer BC, 
Johnson LA, Hanson AJ. Effects of apolipoprotein E on nutritional metabolism in 
dementia. Current Opinion in Lipidology. 2019 Feb. PMID: 30550413] 
1.1 Introduction 
 Apolipoprotein E (ApoE) is the major apolipoprotein in the central nervous system, 
responsible for lipid transport and cholesterol homeostasis. The gene that encodes ApoE 
(APOE) has three human isoforms– E2, E3, and E4 – with population frequencies of 8.4%, 
77.9%, 13.7% respectively. The APOE gene has attracted much attention as the strongest 
genetic risk factor for the development of late onset Alzheimer’s Disease (AD). Carriage 
of the E4 allele substantially raises one’s risk of developing late onset AD, whereas the E2 
allele is protective.(1) A new appreciation is forming for the role of APOE in cerebral 
metabolism of both glucose and lipid substrates. In this chapter, I will summarize recent 
findings in both humans and experimental APOE mouse models.  
 AD is characterized by several neuropathological hallmarks, including 
accumulation of extracellular amyloid plaques, intracellular tau tangles, and metabolic 
abnormalities including disruption of glucose metabolism and mitochondrial 
dysfunction.(2)  The mechanisms by which E4 carrier status influences or causes these 
pathologies are still unclear, but there are likely both amyloid dependent and independent 
effects.  Although it only differs from E3 and E2 by one or two amino acids, the structure 
of apoE4 protein is more compact and unstable which alters its ability to bind lipid, and in 
turn bind and clear amyloid breakdown products from the brain.  The E4 isoform also 
appears to alter mitochondrial function, interfere with insulin signaling, and increase lipid 
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oxidation.(2) E4 carriers also demonstrate more pronounced and earlier defects in cerebral 
glucose metabolism.(3, 4)  The effects of E4 are numerous, and many of the pathologies 
appear to involve cerebral energy metabolism, suggesting nutritional interventions could 
delay or prevent cognitive decline in these individuals.(4) 
1.2 APOE influences the connection between diet and brain health 
Abundant epidemiologic evidence shows high fat diets (HFD) and resultant 
metabolic abnormalities such as obesity and insulin resistance are risk factors for AD.(5, 
6)  Importantly, these findings are often modulated by APOE genotype.  The association 
between HFD and AD in human epidemiological work is limited to E4 non-carriers in 
some(7, 8) but not all studies.(9)  For example, we showed that acute high fat feeding 
improved cognition and plasma AD biomarkers in E4 carriers, but worsened these 
biomarkers in E4 non-carriers.(10)  Reasons for this paradoxical response to HFD in E4 
carriers is unknown, and could involve differences in transport of macronutrients, 
differences in lipidation status of the apoE protein, or differences in insulin and glucose 
metabolism.(2, 11, 12)   
One major consequence of HFD is peripheral insulin resistance, which decreases 
brain insulin transport and subsequent function.(13) Both E4 carriers and non-carriers with 
AD have reduced CSF insulin and demonstrate signs of brain insulin resistance. However,  
the relationship between peripheral and brain insulin, and the connection between insulin 
resistance and brain aging, is less established in E4 carriers.(14-16) Similarly, E4 status 
influences the correlation between Aβ and insulin resistance.  Only E4 non-carriers showed 
a correlation between CSF Aβ and CSF:plasma glucose ratio,(15) and showed reduced 
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plasma amyloid and memory improvement after an insulin infusion; E4 carriers had no 
changes in memory and their plasma amyloid increased in response to insulin.(17)  
Additionally, in an acute meal study, E4 non-carriers showed an increase in plasma Aβ42 
after a high-fat meal compared to a high carbohydrate meal. Conversely, E4 carriers 
demonstrated higher plasma Aβ after the high carbohydrate meal accompanied by larger 
changes in insulin.(10)  Given the brain insulin dysfunction in AD patients, insulin 
sensitizers and intranasal insulin are being investigated as treatments, and although the data 
are mixed, and the majority of these treatments improve cognition only in E4 non-
carriers.(12)  
Promisingly, healthy diets and certain nutritional factors improve cognition and 
reduce AD risk, but these findings are also influenced by APOE genotype. Perhaps the best 
studied diet for AD prevention is the Mediterranean (MeDi).(18)  Most studies which have 
demonstrated cognitive or AD biomarker benefits of MeDi included APOE genotype as a 
covariate.(19-21) However, few if any have done pre-specified subgroup analyses by 
APOE status. A multicomponent interventional study involving a diet similar to MeDi 
showed that 2 years of a healthy Nordic diet (abundant fish, fruits and vegetables), exercise 
and brain training can prevent cognitive decline, although adherence to diet was not tracked 
and the control group also received information about the diet.(22) A subgroup analysis 
revealed that E4 carriers benefited more on tests of cognition from this intervention.(23) In 
another study, a hybrid Mediterranean diet was found to be protective against incident AD, 
but less protective in E4 carriers.(24) 
Seafood intake is another dietary pattern associated with slower cognitive decline, 
but in one study this finding was only noted in E4 carriers.(25) Seafood contains high levels 
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of polyunsaturated fatty acids, or PUFAs, including DHA and EPA, and high intake of 
these nutrients is protective against AD. Despite the stronger protective effect of seafood 
in E4 carriers, studies specifically examining PUFAs show more benefit in non-carriers.  
In an intervention study in older adults, E4 non-carriers who received DHA for 18 months 
declined significantly less on a cognitive test compared to placebo, whereas DHA had no 
effect on E4 carriers.(26)   In another study, there was a stronger association between fish 
consumption and increased plasma DHA levels in E4 non-carriers, whereas in E4 carriers 
there was a positive association between meat and DHA.(27) Follow-up studies have 
suggested several potential mechanisms, including decreased lipoprotein lipase activity 
and differential fatty acid processing, increased VLDL turnover, or higher levels of lipid 
peroxidation and beta-oxidation in E4 carriers.(27, 28) How these peripheral differences 
affect brain transport and utilization of PUFAs and other FFA remains unknown. (27, 28)    
Since patients with AD have decreased cerebral glucose metabolism, diets and 
pharmacologic agents which induce ketosis and supply the brain with ketone bodies are 
being investigated as treatments.(29) Although E4 carriers have more pronounced and 
earlier cerebral glucose dysregulation, only E4 non-carriers with AD responded to a 
ketosis-inducing medium-chain triglyceride supplement.  The authors speculated that the 
mitochondrial dysfunction in E4 carriers, renders this group less able to use ketone bodies 
in lieu of glucose for brain fuel; alternatively there could be differences in ketone body 
brain transport.(30)  
The evidence continues to accumulate around the idea that APOE genotype 
influences cognitive and neurological responses to diet and dietary supplements. To 
understand the pathophysiology of diet and dementia risk, in vitro and in vivo mouse 
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models serve as ways to examine these mechanisms more carefully. As noted above, HFD 
and resultant metabolic abnormalities have been identified as risk factors for AD.(5, 6)  
The saturated FFA palmitate induces inflammation in cell lines and AD animal models.(31, 
32)  However most human cell lines are studied without respect to APOE status, and the 
most utilized rodent models of AD which have provided much of the data for the 
experimental link between dietary factors and AD pathology are analogous to E4 non-
carriers.(33) However, new models of human induced pluripotent stem cells (iPSC) edited 
to include APOE3 and APOE4 hold promise, and recent studies have demonstrated 
important differences in function with respect to lipid and cholesterol metabolism in 
neuronal- and glial-derived iPSCs.(34)  In the next sections we will discuss how humanized 
APOE mice can help us better understand the differences we are seeing in vivo, in particular 
the response to high fat diets and lipid-based therapies in E4 carriers.  
1.3 Knowledge and tools available to study APOE effects on nutritional metabolism in 
dementia 
Research into the effect of APOE on nutritional metabolism has often relied on 
mouse models as a correlate for human disease. While several mouse models of human 
APOE exist (Table 1.3.1), the most widely used are the targeted replacement (TR) mice 
developed by Sullivan et al in the laboratory of Dr. Nobuyo Maeda. These mice were 
created by mating C57BL/6J mice with chimeras whose embryos had been injected with 
embryonic stem cells electroporated with human APOE2, APOE3, or APOE4 
constructs.(35) The vector was inserted at the normal murine APOE locus to maintain 
physiologic expression of the human variant. The metabolic profiles of these mice have 
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been explored by many groups, specifically with respect to how they differ from wild type 
mice and humans.  
While 5-10% of human E2 homozygotes develop type II hyperlipoproteinemia, all 
E2 TR mice display features of it, including spontaneous atherosclerosis, xanthomas, and 
decreased VLDL clearance.(36) It has been hypothesized that this is due to the low affinity 
of E2 for the main VLDL receptor, LDLR. While humans are able to clear VLDL through 
apoE independent mechanisms (apoB100-LDLR interactions) mice are wholly dependent 
on apoE for clearance, and thus magnify functional differences in the apoE isoforms. While 
the abnormal lipid profile confounds studies of E2’s lipid associated role in mitigating AD 
risk, the model is still useful for probing alternative roles of E2. For example, some have 
posited that E2 provides a metabolic advantage and thereby decreases AD risk. Venzi and 
colleagues found E2 mice to exhibit a significant increase in cerebral glucose metabolism 
beyond 3 months of age. Compared to E3 mice at 6 months, E2 mice showed increased 
glucose uptake by [18F]FDG imaging in whole brain, cingulate cortex, cortex, and 
hippocampus and then a global increase at 9 months of age.(37)  However, the first 
comprehensive human study to examine E2 carriers with [18F]FDG imaging showed that 
age-related decreases in glucose uptake did not significantly differ from E3 
individuals.(38) Thus, the cerebral metabolic effects of E2 remain an important, but 
unsettled issue. 
The E3 and E4 TR mice also express their human isoforms at physiologic levels.(35, 
36, 39) They are normolipidemic but become hyperlipidemic in response to a westernized 
diet.(36, 40) While E4 confers a higher risk of dementia in humans, it is controversial what 
cognitive effects are present in in TR E4 mice (in the absence of amyloid or tau over 
7 
 
expressing mutations). Rodriguez and colleagues observed impairments in spatial learning 
and memory in young E4 TR mice in the Barnes maze test, but no difference in a hidden 
platform water maze experiment.(41) In contrast to mixed effects of E4 on behavioral 
outcomes and age-related cognitive decline, the association of E4 with cerebral metabolic 
changes is more clear.  Several groups have demonstrated reductions in cerebral glucose 
uptake in E4 mice compared to mice expressing E3 (42-44)  – similar to the well-
established findings via FDG PET in human E4 carriers.  
In humans, E4 carrier status is associated with a higher brain amyloid burden, but it 
has been more difficult to demonstrate this in E4 mice unless other AD-related genes are 
present.(11)  When AD mice are crossed with APOE knockout mice, the resultant 
phenotype is less amyloid depositions, suggesting that the apoE protein is necessary for 
amyloid breakdown products to cause plaques. AD mice that express human APOE alleles 
do recapitulate what is seen in humans with more amyloid in E4 compared to E3, and less 
still in E2.(45) One important difference that may affect amyloid burden studies is that 
humanized E4 is less stable in mouse brain and is degraded, whereas this does not appear 
to be the case in humans.(11, 46) 
As glucose uptake and utilization is impaired in E4 carriers and AD individuals, 
many groups have studied the insulin-signaling pathway as a potential target of APOE 
modulation. Hippocampal RNA from middle-aged female E2, E3, and E4 TR mice was 
arrayed for genes involved in insulin signaling. This revealed that E2 mice have higher 
levels of Igf1, insulin receptor substrates, and the glucose transporter GLUT4 than E3 and 
E4.(47) Furthermore, E4 mice showed a significant decrease in PPAR-gamma and insulin-
degrading enzyme, pointing to a further compromise of insulin signaling and glucose 
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utility. These findings were confirmed by another group who used an array for glucose and 
ketone body metabolism and identified glucose transporters and hexokinases were robustly 
altered by APOE genotype.(48) The Bu group discovered that E4 restricts insulin receptors 
to endosomes and thereby impairs trafficking and signaling, an effect exacerbated by 
HFD.(49) To test the effect of APOE on peripheral insulin receptor sensitization, To et al. 
fed E3 and E4 mice a diabetogenic diet then treated the mice with a thiazolidinedione. They 
found a reduction in tau phosphorylation, but only in E3 mice.(50) These studies support 
the idea that E4 renders the brain insulin resistant, likely through regulation of insulin 
receptors and glucose transporters. 
Despite growing evidence for a role of diet in AD and the potential of personalized 
medicine and gene-diet interactions, very few studies have attempted to tackle the 
interaction between APOE and diet in the context of AD or cognitive function. Our group 
explored the potential interactive effects of diet and E4 on cognition by using a mouse 
model of chronic high fat feeding. We found that disruption of glucose homeostasis 
following 6 months of HFD led to more pronounced cognitive impairments in E4 compared 
to E3 mice. These cognitive deficits were specific to hippocampal-dependent spatial 
learning and memory outcomes, and were accompanied by wide-ranging isoform-specific 
alterations in the epigenetic landscape and changes in cerebral metabolism.(51) It is 
hypothesized that its effects on cerebrovascular function could be the driving force of the 
cognitive impairing effects of HFD. We found that E4 mice fed a HFD exhibit reduced 
glucose uptake compared to both E4 mice on a control diet and E3 mice on both control 
and HFD.(51) Further, E4 carriage and HFD acted synergistically to lower cerebral blood 
flow.(43)  Interestingly, when challenged with an acute glucose bolus, E4 but not E3 mice 
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responded beneficially in terms of both increased blood flow and enhanced performance 
in a memory task; hinting at a potential role for APOE in modulating neurovascular 
coupling and cognitive function. (43) 
In the APP mouse model of distorted amyloid processing, expression of E4 along 
with a HFD significantly increases amyloid deposition compared to E3.(52) E4 was also 
found to increase amyloid and glial activation in the EFAD model of AD when fed a 
westernized diet. (53) E3 mice gain more weight on a HFD, while E4 mice seem to 
upregulate genes involved in fatty acid mobilization and utilization in the periphery.(54) 
This could parallel a central E4 promoted HFD induced bioenergetic shift toward fatty 
acids and away from glucose as the primary cerebral energy source. Together, these studies 
show that E4 seems to exacerbate the negative effects of a HFD on cognition. 
1.4 Conclusions 
As we continue to uncover the role of the APOE gene as a contributor to cognitive 
decline, we must take into account the additive effects that the westernized high fat diet 
and insulin resistance seem to have on disease progression. Human epidemiologic and 
experimental evidence suggests that APOE genotype changes the relationship between 
several lipid-related macronutrients and markers of brain health and cognition. Whether it 
is diet-induced insulin resistance, PUFAs from fatty fish, or ketone bodies from medium 
chain triglycerides, APOE status appears to modulate important responses to lipid-related 
therapies. Mouse models have been vital in confirming that E4 exacerbates the negative 
cognitive effects of diabetogenic and HFD, and also suggest reasons by which E2 carriers 
are less susceptible to developing AD. Future studies should utilize these and other 
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experimental models of APOE to implicate specific cells and tissues in the E4 response to 
nutritional interventions, and include APOE genotype as an important subgroup for 



















Table 1.1 Summary of APOE Models by Expression and Original Report or Source 
Model APOE Expression Original Study 
Targeted Replacement Mice Global E2, E3, E4 Sullivan et al. 1997(35) 
NSE Promoter Neuron Raber et al. 1998(55) 
GFAP Promoter Astrocyte Sun et al. 1998 
Dox Inducible Cell specific Liu et al. 2017(56) 
APOE* KI mice Global E2, E3, E4 Jackson Laboratory 
hApoE4 Knock-in Rat Global E4 Horizon Discovery 




CHAPTER 2. APOE4 LOWERS ENERGY EXPENDITURE BY INCREASING FLUX 
THROUGH AEROBIC GLYCOLYSIS 
[This chapter consists of material adapted from a submitted manuscript that is under 
review. For supplementary materials pertaining to this chapter, see appendix 1.] 
ABSTRACT 
Cerebral glucose hypometabolism is consistently observed in individuals with 
Alzheimer’s disease (AD) and also in young cognitively normal carriers of the Ε4 allele of 
Apolipoprotein E (APOE). As Ε4 is the strongest genetic predictor of late-onset AD, 
identifying other metabolic signatures of young Ε4 carriers may provide insight into 
disease mechanisms and early screening criteria for AD. Here, we perform the first 
assessment of whole body energy expenditure (EE) in young and middle-aged human 
participants with and without the Ε4 allele. Strikingly, young female Ε4 carriers show a 
lower resting EE than non-carriers - a phenomenon exaggerated following a dietary glucose 
challenge due to stunted oxygen consumption. This Ε4 effect was not observed in middle-
aged individuals, suggesting an “early-aged” Ε4 phenotype of oxidative impairment. When 
given a cognitive challenge, EE increased in all study volunteers, representing a strong 
cerebral contribution to EE. Plasma metabolites associated with glycolysis were elevated 
in Ε4 carriers and pathway analyses revealed a glucose-induced increase in aerobic 
glycolysis (i.e. the Warburg effect). Isotopic tracing of 13C-glucose in mice and astrocytes 
expressing human APOE showed Ε4-associated increases in lactate synthesis and 
decreased pyruvate entry into the TCA cycle. Finally, E4 astrocytes had elevated glycolytic 
activity, decreased oxygen consumption, blunted oxidative flexibility, and a lower rate of 
glucose oxidation in the presence of lactate. Together, these results suggest system-level 
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metabolic reprogramming in young Ε4 carriers, an endophenotype observable by indirect 
calorimetry and plasma metabolomics decades prior to clinically manifest AD.   
2.1 Introduction 
The Ε4 allele of Apolipoprotein E (APOE) confers more risk for the development 
of late-onset Alzheimer’s disease (AD) than any other gene (58, 59). While E4 is a strong 
contributor to late-onset AD risk, the effect is even greater in females (60). Female E4 
carriers have an increased odds ratio for AD (61), increased incidence of AD (62), elevated 
hazard ratio for conversion to mild cognitive impairment (63), increased CSF tau (64), and 
reduced hippocampal volume (65), compared to male E4 carriers. To date, studies 
investigating the mechanism by which Ε4 and sex increase disease risk have primarily 
focused on the important associations of Ε4 with the neuropathological hallmarks of AD – 
i.e. the increased amyloid load seen in Ε4 carriers (66, 67) and the APOE-dependence of 
tau propagation (68, 69).  
Alternatively, investigating Ε4 carriers who have not yet developed neuropathology 
may provide insight into early E4 mechanisms and unveil additional risk factors for AD. 
For example, an early and consistent biological hallmark of AD is cerebral glucose 
hypometabolism as observed by 18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET) imaging (70-72). Interestingly, Ε4 carriers also display an AD-like pattern of 
decreased glucose metabolism by FDG-PET long before clinical symptomology (3, 73). 
Since glucose hypometabolism occurs early in AD and early in Ε4 carriers, it may represent 
a critical initial phase of AD pathogenesis that predisposes individuals to subsequent 
symptomology. Beyond this FDG-PET finding, it is not clear if APOE has other 
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discernable metabolic effects in pre-cognitively impaired young people. Studying APOE’s 
association with glucose metabolism in Ε4 carriers decades prior to disease onset may be 
beneficial in designing early interventions for the metabolic derangements of AD. 
In contrast to the robust FDG-PET literature, clinical research focused on how 
APOE may regulate metabolism outside of the brain is limited (74). Most studies have 
utilized a targeted replacement mouse model of APOE in which the murine Apoe alleles 
are replaced by the human orthologs (35, 75). For example, several studies have found Ε4 
mice to exhibit increased susceptibility to insulin resistance, and one report characterized 
E4 mice as deficient in extracting energy from dietary sources (49, 51, 54). While these 
preclinical studies have been critical to our understanding of Ε4-associated impairments in 
glucose metabolism, the extent to which systemic glucose metabolism is regulated by 
APOE in young healthy humans is largely unknown.  
Energy expenditure (EE) is defined as the energetic cost of processes essential for 
life. Indirect calorimetry (IC) assesses EE by measuring metabolic gases to calculate the 
energy released when substrates are oxidized, and is the gold standard in the clinical setting 
to assess nutritional status and dietary needs (76). The Weir equation (EE = 3.9 * VO2 + 
1.11 VCO2) estimates EE with the assumption that anaerobic respiration is negligible and 
substrates are fully oxidized to CO2 (77). This assumption is confounded when energy is 
derived through non-oxidative processes such as aerobic glycolysis - when glucose is 
metabolized to the non-oxidative metabolite lactate rather than pyruvate despite normoxia 
(78). Increased flux through glycolysis also decreases EE since only 2 ATP are produced 
via glycolytic substrate level phosphorylation in contrast to the 34 ATP from oxidative 
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phosphorylation. Therefore, individuals who undergo extensive aerobic glycolysis show a 
low EE due to less oxygen consumption and less ATP turnover.   
Here, we use IC to study APOE genotype-dependent metabolic phenotypes in 
healthy, cognitively normal young and middle-aged individuals. We observe that young 
E4 carriers expend significantly less energy at rest and exhibit greater utilization of the 
aerobic glycolysis pathway, as evidenced by elevated lactate abundance in the plasma 
metabolome. Additionally, Ε4 carriers and Ε4 mice displayed an inability to increase 
oxygen consumption after a high carbohydrate challenge – a sign of oxidative impairment 
consistent with aerobic glycolysis (79). In vitro studies in astrocytes indicate that these 
energy detriments are a result of increased glycolytic flux, thereby increasing lactate 
production at the expense of oxidative metabolism. Together, these findings point to a role 
for APOE as a critical regulator of systemic glucose metabolism.  
2.2 Methods 
2.2.1 Study Design 
The study objectives were to i) determine if APOE genotype influences peripheral 
and cerebral metabolism in young cognitively normal human subjects, and if so, ii) 
elucidate potential mechanisms using mouse and cell models of human APOE.  For the 
clinical research study, healthy volunteers between 18-65 were prescreened for diagnoses 
that may affect cognitive function (ex. stroke, Parkinson’s), metabolic diseases (diabetes), 
alcoholism, drug abuse, chronic major psychiatric disorders, medications that interfere 
with cognition (narcotic analgesics, anti-depressants), medications that interfere with EE 
(stimulants, beta-blockers) and vision or hearing deficits that may interfere with testing. 
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The prescreening checklist with a full list of medications and conditions excluded for can 
be found in the supplemental materials. Eligible candidates were brought in for informed 
consent after a 12-hour fast in which subjects were asked not to exercise and to abstain 
from everything except for water. We employed a power analysis based on a feasibility 
study, and the required sample size per group for a power level of 0.9 was calculated to be 
n = 30 per “group” (i.e. E2+, E3/E3 and E4+), for a total of 90 subjects. To account for 
potential biological outliers, non-consenting subjects, and post-recruitment exclusion 
criteria being met, we recruited a total of 100 individuals for this observational study. Six 
individuals who had IC values more than 2 standard deviations from the mean were 
excluded from analysis leaving 94 individuals for analysis. As we were primarily interested 
in APOE effects in young individuals, we stratified our sample population into a young 
cohort (under 40 years old) and a middle-aged cohort (40-65 years old). We chose 40 as 
the age-cutoff based on a meta-analysis of APOE genotype and AD-risk which found the 
Ε4 effect on disease to be observable in individuals 40 and over (61). Data acquisition was 
blinded as APOE genotypes were determined after the study.  
 
2.2.2 Human study 
Body mass index (BMI), waist to hip ratio, and blood pressure were first recorded. 
Thereafter, participants were fitted with an airtight mask that was connected to an MGC 
Diagnostics Ultima CPX metabolic cart which measures VO2, VCO2, and respiratory rate. 
EE is defined as the amount of energy an individual uses to maintain homeostasis in kcal 
per day, and can be calculated using the Weir equation (EE = 1.44 (3.94 VO2 + 1.11 VCO2) 
(77). EE is composed of the resting energy expenditure (REE), the thermic effect of feeding 
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(TEF), and activity related energy expenditure (AEE). In motionless and fasted humans, 
EE is equivalent to the REE since the TEF and AEE have been controlled for. Participants 
were instructed to remain motionless and to refrain from sleep for 30 minutes as data was 
gathered. All testing occurred between 8:30-11:30 am in a temperature controlled (20–22 
°C) out-patient research unit (Center for Clinical and Translational Science, University of 
Kentucky). Body temperature was taken periodically via temporal thermometer to ensure 
thermostasis and provide intermittent stimulation to ensure wakefulness. After the resting 
period came a 30 minute cognitive test period. We then introduced a novel-image-novel-
location (NINL) object recognition test consisting of a series of images which participants 
were later asked to recall. This test has been shown previously to study APOE allele effects 
on cognition (80). After the cognitive test period, a blood draw was taken via venipuncture 
and placed on ice. Participants then consumed a sugary milk drink consisting of 50g of 
sugar dissolved in whole milk. The drink was consumed within a two minute time span. 
The mask was then refitted and participants were instructed to again remain motionless for 
30 minutes for data collection. Data from the first 5 minutes of the study time periods were 
excluded to allow a five minute steady state adjustment (81, 82). After the glucose 
challenge, participants provided a second blood sample (~45 minutes after the initial blood 
draw). Participants then exited the study and were compensated for their participation. This 
study was approved by the University of Kentucky Institutional Review Board (#48365) 





APOE genotype was determined by extracting genomic DNA from participants’ 
blood samples using a GenElute Blood Genomic DNA Kit (Sigma). After confirming 
concentration and quality by Nanodrop, APOE genotype was determined using PCR with 
TaqMan assay primers for the two allele-determining SNPs of APOE: rs7412 and rs429358 
(Thermo). Positive controls for the six possible APOE genotypes were included with each 
assay. 
 
2.2.4 Plasma metabolomics 
Plasma was separated from blood by centrifugation at 2500 x g for 10 minutes at 
4°C, and stored in 200uL aliquots at -80°C until further use. Upon thawing, ice cold 100% 
methanol solution containing 40nM L-norvaline (internal standard) was added to 80 ul of 
plasma and kept on ice for 20 minutes with regular vortexing. The solution was then 
centrifuged for 10 minutes (14,000 rpm, 4°C). Supernatant containing polar metabolites 
was removed to a new tube and kept at -80°C until prepped for GCMS analysis (additional 
details in Supplemental Methods). 
 
2.2.5 Mice 
Mice expressing human APOE display many of the phenotypic characteristics 
observed in humans including several metabolic variations noted in epidemiological 
studies (83-85). In this “knock-in” model, the mouse Apoe locus is targeted and replaced 
with the various human APOE alleles, thereby remaining under control of the endogenous 
19 
 
mouse Apoe promoter and resulting in a physiologically relevant pattern and level of 
human APOE expression (3, 36, 86-89). Mice used in this study were homozygous for 
either the human E3 or E4 alleles, aged 2-4 months (young) and housed in sterile micro-
isolator cages (Lab Products, Maywood, NJ), and fed autoclaved food and acidified water 
ad libitum. Animal protocols were reviewed and approved by the University of Kentucky 
Institutional Animal Use and Care Committee. 
 
2.2.6 Metabolic phenotyping  
Human E3 and Ε4 mice were evaluated by indirect calorimetry (TSE Systems, 
Chesterfield, MO). Mouse body composition was measured using EchoMRI (Echo 
Medical Systems, Houston, TX) the morning prior to being singly housed in the indirect 
calorimetry system. Mice were acclimated to singly housed cage conditions for one week 
prior to beginning data recording. After five days on standard chow diet (Teklad Global 
18% protein rodent diet; 2018; Teklad, Madison, WI), mice were fasted overnight before 
being introduced to a high carb diet (Open Source Diets, Control Diet for Ketogenic Diet 
with Mostly Cocoa Butter, D10070802) for five days. Mice were monitored for O2 
consumption, CO2 production, movement, and food and water consumption. Chambers 
were sampled in succession and were reported as the average of 30 minute intervals in 
reference to an unoccupied chamber. To negate the effects of activity on EE readouts, we 
chose to only analyze the light cycles of the mice where activity, and feeding, is minimal. 
The EE then becomes analogous to a “resting” EE similar to the resting period in the human 
study and differences observed are likely due to basal metabolic rate differences instead of 




2.2.7 Cell culture 
Primary astrocytes were isolated from postnatal day 0-4 pups of mice homozygous 
for E3 or Ε4. The brain was surgically excised and meninges were removed from cortical 
tissue in cold DMEM. Tissue from pups of the same genotype was pooled and coarsely 
chopped to encourage suspension. Tissue homogenates were incubated in serum free 
DMEM with 0.25% trypsin and DNAse for 30 min with gentle shaking. Cell suspension 
was then filtered through 40 µm strainer and spun for 5 min at 1100 x g. Suspended primary 
cells were then plated in a poly-lysine coated plate and allowed to grow to confluency in 
Advanced DMEM (Gibco) with 10% FBS. Immortalized astrocytes were derived from 
targeted replacement mice expressing human APOE alleles (kind gift from Dr. David 
Holtzman). These immortalized cell lines secrete human ApoE in HDL-like particles at 
equivalent levels to primary astrocytes from targeted replacement APOE knock-in mice 
and have been relied upon for studies of APOE’s role in astrocyte metabolism by several 
groups (91-93). Cells were maintained in Advanced DMEM (Gibco) supplemented with 
1mM sodium pyruvate, 1X Geneticin, and 10% fetal bovine serum unless otherwise noted. 
 
2.2.8 Statistical analysis 
All results are reported as mean +/- SEM unless otherwise stated. For comparisons 
between two groups, an unpaired two-tailed Student’s t-test was used. For pair-wise 
comparison of two time points a paired two-tailed Student’s t-test was used. One-way 
analysis of variance (ANOVA) was used for comparing multiple groups followed by 
Sidak’s multiple comparisons test. Two-way ANOVA with repeated measures was used 
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for time course analysis. Pearson r correlation test was used for correlative analysis. For 
dependent variables with categorical independent variables we analyzed covariance 
(ANCOVA) to assess collinearity. P<0.05 was considered significant.  
2.3 Results 
2.3.1 Young female Ε4 carriers have a lower resting energy expenditure 
We first used IC to test the effect of APOE on whole body metabolism in a cohort 
of healthy volunteers (Tables 2.1 and 2.2). Using a mobile metabolic cart designed to 
measure VO2 and VCO2, we assessed volunteers at rest, during a cognitive task, and after 
a glucose challenge (Fig 2.1A, Fig S1). Blood samples were collected before and after the 
glucose challenge to determine APOE genotype and to quantify metabolite abundance by 
mass spectrometry (Fig 2.1B, Table S1). 
We began each session by assessing the resting energy expenditure (REE) and 
respiratory exchange ratio (RER) of participants. After a five-minute buffer to achieve 
steady state (81, 82), we recorded REE over a 25 minute period at 15 second intervals and 
averaged the RER and REE for each individual. There was no APOE effect on RER (Fig 
S2). Consistent with previous studies, we found REE and age to be negatively correlated 
(Fig 2.1C). However, when we stratified our analysis by E4 status, linear regression 
revealed significantly different slopes between Ε4 carriers and non-carriers. While Ε4 non-
carriers fit the overall correlation of age and REE, E4+ individuals did not fit this model 
and showed no deviation from the zero slope (Fig 2.1D), suggesting an Ε4-associated 
confound in the age versus energy expenditure relationship.  
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To determine if the E4 effect on REE was age dependent, we separated Ε4+ and 
Ε4- individuals into young (<40 years of age) and middle aged (40-65 years of age) cohorts 
based on previous literature (3, 61). To account for known influences on energy 
expenditure, we performed one-way analysis of covariance (ANCOVA) using average 
REE values as the dependent variable, E4 status as the independent variable, and age, sex, 
lean body mass (LBM), and body mass index (BMI) as covariates. After adjusting for the 
covariates, we observed a significantly lower REE in female Ε4 carriers compared to non-
carriers, particularly in the young cohort (Fig 2.1E). This E4 effect on REE was not 
significant in males (Fig S3A-B). Together, these data suggest that there is no age-related 
REE decline in E4 carriers, and that the REE-APOE interaction is modified by sex, with 
female Ε4 carriers displaying lower REE. 
 
2.3.2 Ε4 does not alter cognitive energy expenditure  
We next tested if a cognitive intervention would reveal further APOE genotype-
specific differences in EE. To avoid potential confounding readouts of movement, subjects 
were asked to remain perfectly still while completing a challenging Novel Image Novel 
Location test (Fig S1C). We observed a significant increase in average EE during the 
cognitive challenge in all subjects, regardless of age or APOE status (Fig 2.1F). To assess 
cognitive energy expenditure (CEE), we determined the max EE during the cognitive test 
period and subtracted the average REE for each subject. We found no difference in CEE, 




2.3.3 Female Ε4 carriers have a lower thermic effect of feeding and fail to increase VO2 
after a glucose drink 
We next sought to measure the thermic effect of feeding (TEF) - a constituent of 
EE that indicates the energy used to absorb, digest, and metabolize dietary energy (94, 95). 
To induce TEF, all participants consumed a high carbohydrate drink in less than two 
minutes (Fig S1D). Energy expenditure during the dietary challenge increased significantly 
in all participants (Fig 2.1H). To account for covariates during the glucose period, we 
performed two-way ANCOVA using time and IC values as dependent variables, E4 status 
as the independent variable, and age, sex, LBM, and BMI as covariates. TEF was calculated 
by subtracting the average REE from the maximum of EE after the glucose challenge for 
each subject. Similar to resting EE, female E4 carriers displayed a significantly lower TEF 
than non-carriers, particularly in the young cohort (Fig 2.1I).  
We next sought to understand if there were APOE-dependent alterations in VCO2 
and VO2 in the response to the glucose challenge. Plotting the time course of EE after 
participants consumed the glucose drink revealed a dramatically blunted EE response in 
E4+ subjects (Fig 2.2A). Further stratification by individual genotypes showed a clear 
stepwise effect of APOE (Fig 2.2B). Plotting the VCO2 values revealed a similar, but non-
significant trend of lower CO2 production in E4 carriers (Fig 2.2C-D). Analyzing the rate 
of change in VO2, we observed that while non-carriers significantly increased their oxygen 
consumption following the glucose drink, Ε4 carriers did not, as noted by a non-significant 
slope deviation from zero (Fig 2.2E). Additionally, the AUC of VO2 showed significant 
differences by E4 carrier status and individual genotypes (Fig 2.2F).  
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We found the E4 effect on EE and VO2 to be significant and independent of age, 
BMI, and LBM. Interestingly, when we stratified by sex we observed that the covariate-
adjusted E4 effect on EE and VO2 was significant in females but not in males, again 
suggesting a sex-specific phenomenon (Fig S5). As EE is calculated based on VCO2 and 
VO2 values, these results likely reflect decreased oxidation of the glucose drink in female 
E4 carriers. 
 
2.3.4 Targeted metabolomics reveals glycolysis as a differentially regulated pathway in 
Ε4+ plasma 
To determine if the observed APOE differences in energy expenditure were 
reflected in the plasma metabolome, we conducted a targeted metabolomics analysis of 
human plasma samples before and after the glucose challenge (Table S1). A pathway 
analysis of the plasma metabolome before the glucose drink highlighted E4-associated 
differences in glycolysis and pyruvate metabolism (Fig 2.3A). Further analyses of 
individual metabolites revealed lactate as the metabolite most strongly affected by E4 
carriage (Fig 2.3B). Indeed, E4 carriers displayed dramatically higher plasma lactate 
concentrations before and after the glucose drink (Fig 2.3C; Fig S6). Following the glucose 
challenge, there was an increase in the number of carbohydrate processing pathways and 
metabolites that were differentially altered in Ε4 carriers (Fig 2.3D-E). A pathway 
enrichment analysis highlighted multiple E4-associated changes, with top hits including 
“Warburg effect” and “Transfer of acetyl groups into mitochondria” (Fig 2.3F). Together, 
analysis of the plasma metabolome from cognitively normal young and middle-aged Ε4+ 




2.3.5 Ε4 mice fail to increase energy expenditure on a high carbohydrate diet 
We next asked if the metabolic effects of APOE on EE would translate to a 
humanized mouse model of APOE. Since mouse IC cages allow for a prolonged and 
controlled assessment of metabolism, we provided a long-term glucose challenge by way 
of a high carbohydrate diet (HCD). Similar to the decreases observed in E4 humans, young 
mice carrying the human E4 allele exhibited significantly lower EE, VCO2, and VO2 
compared to young E3 mice during their inactive period (light cycle) (Fig 2.4A). Following 
introduction of a HCD, these decreases were exaggerated; Ε4 mice again showed 
substantially lower EE, VCO2, and VO2 compared to E3 mice (Fig 2.4B).  
We next analyzed the HCD-induced change in EE, VCO2, and VO2 from baseline 
(normal chow). We found both genotypes to show significant positive changes except for 
E4 VO2 (Fig 2.4C), suggesting that E4 mice fail to increase oxygen consumption in 
response to excess dietary carbohydrates. These changes occurred independently of 
differences in activity and food intake, as there was minimal activity or feeding during the 
light cycle (the period used for analysis) in both groups (Fig S7A-B). Further, ANCOVA 
revealed dissimilar correlations between body weight and EE between genotypes 
indicating the variability in EE cannot be explained by body weight (Fig S7C). These data 
suggest that Ε4 acts in young mice to lower EE via a mechanism outside of the typical 




2.3.6 Stable isotope resolved metabolomics (SIRM) reveals increased lactate synthesis 
and decreased entry into the TCA cycle in Ε4 brains and astrocytes 
Given the decreased VO2 observed in E4 mice and humans and increased plasma 
lactate concentrations in Ε4+ subjects, we hypothesized that these individuals were 
diverting a higher fraction of glucose to aerobic glycolysis as opposed to oxidative 
phosphorylation. To test this, we employed 13C tracer metabolomics to quantitatively 
assess glucose utilization in mice and primary astrocytes expressing human APOE (Fig 
2.5A). Fasted E3 and Ε4 mice were administered an oral gavage of fully labeled [U-13C] 
glucose and brain tissue was collected 45 minutes later for mass spectrometry analysis of 
13C enrichment in central carbon metabolites. The brains of Ε4 mice showed significantly 
higher 13C-lactate (fully labeled, m+3) compared to E3 mice (Fig 2.5B). Additionally, 
enzyme activity measures of pyruvate dehydrogenase (PDH) – the primary entry point for 
pyruvate into the TCA cycle via acetyl-CoA – showed a trend toward lower activity in Ε4 
compared to E3 brain tissue, while lactate dehydrogenase (LDH) – the enzyme responsible 
for interconversion of pyruvate and lactate – showed a trend toward higher activity (Fig 
2.5C). 
As astrocytes are the primary source of both cerebral lactate (96) and ApoE (89), 
we next utilized SIRM to measure glucose utilization in vitro in primary astrocytes 
expressing human APOE. E4 astrocytes showed a significant increase in both LDH activity 
and in 13C-glucose conversion to lactate (Fig 2.5D-E), and as expected, lactate generation 
was higher in this glycolytic cell type compared to whole brain homogenates (Fig 2.5B). 
Conversely, E4 astrocytes displayed substantially lower 13C enrichment of TCA 
intermediates, suggesting decreased glucose entry into the TCA cycle (Fig 2.5F). To 
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confirm these results, we performed an independent 13C-glucose tracing experiment in 
immortalized astrocytes expressing human E3 or Ε4 (97) and quantified 13C-lactate 
production using nuclear magnetic resonance spectroscopy (Fig 2.5G-H). Again, Ε4 
astrocytes showed significantly higher lactate synthesis, as evidenced by increased 13C-
lactate both intracellularly and in the media (Fig 2.5I). Together, these data describe an Ε4-
associated increase in glucose flux into late glycolysis at the expense of entry into the TCA 
cycle for oxidative phosphorylation. 
 
2.3.7 Ε4 astrocytes exhibit impairments in glucose oxidation  
To functionally assess glycolytic flux in vitro, we measured the extracellular 
acidification rate (ECAR, a marker of glycolysis and lactate export) before and after 
glucose injection (Fig 2.6A). E4 astrocytes displayed significantly higher ECAR after 
addition of glucose compared to E3 astrocytes, suggesting these cells shunt more glucose 
to lactate (Fig 2.6A). Furthermore, Ε4 astrocytes showed a higher glycolytic capacity, as 
shown by a heightened ECAR response to oligomycin - an inhibitor of mitochondrial 
respiration (Fig 2.6B). We then measured glucose oxidation by assessing the oxygen 
consumption rate (OCR). Ε4 astrocytes displayed significantly lower OCR both before and 
after addition of glucose to the media, suggesting an inherent reduction in oxidative 
metabolism in Ε4 astrocytes relative to E3 (Fig 2.6C-D). Together these results further 
confirm an E4-associated shift toward glycolysis (Fig 2.6E).  
We next measured glucose oxidation by treating astrocytes with radiolabeled 14C-
glucose and capturing the oxidative product 14CO2. Ε4 astrocytes oxidized less glucose to 
CO2 compared to E3, but only when the radiolabel ([nM]) was given with a substantial 
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amount of non-labeled glucose ([mM]) (Fig 2.6F). Ε4 astrocytes also displayed decreased 
capacity and flexibility in regards to glucose oxidation, as they were relatively unable to 
increase glucose oxidation when other fuel sources (fatty acids and glutamine) were 
inhibited (Fig 2.6G). We reasoned that lower rates of glucose oxidation in a glucose rich 
environment in E4 cells may be due to increased conversion of glucose to lactate, which in 
turn inhibits downstream oxidative processes (98). Therefore, we tested glucose oxidation 
following lactate supplementation, and found that Ε4 astrocytes oxidize less glucose in the 
presence of lactate than E3 astrocytes (Fig 2.6H). Together, these results suggest that Ε4 
astrocytes exhibit increased reliance on aerobic glycolysis and are less flexible and less 
able to oxidize glucose, a phenotype seemingly exacerbated by a high glucose environment 




In the current study, we used indirect calorimetry to show that APOE4 reduces 
energy expenditure in a cohort of young cognitively normal females, a phenomenon 
exacerbated by a dietary glucose challenge. Analysis of the plasma metabolome revealed 
E4-associated increases in pathways related to carbohydrate processing, specifically 
aerobic glycolysis, highlighted by higher concentrations of the glycolytic end-product 
lactate. By applying stable isotope-resolved metabolomics in vivo and functional assays of 
cellular respiration in vitro, we discovered that both E4 expressing mouse brains and E4 
expressing astrocytes increase glucose flux through aerobic glycolysis at the expense of 
TCA cycle entry and oxidative phosphorylation.  Cumulatively, these data highlight a 
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novel mechanism whereby Ε4 lowers energy expenditure in young women and decreases 
glucose oxidation by redirecting flux through aerobic glycolysis. 
Detecting early symptoms of eventual cognitive decline is important for primary 
prevention of AD (99). Drugs advanced as potential AD therapeutics have targeted 
pathways associated with neuropathology, such as tau anti-sense oligonucleotides and 
amyloid-directed monoclonal antibodies (100). Given the largely disappointing trial 
outcomes, these therapies may be intervening after a ‘point of no return’ and thus offer 
minimal benefit in prognosis (101). In order to design therapies for early interventions in 
those at risk for AD, we must first identify measurable biomarkers whose severity and/or 
change over time correlate with risk for clinically observable AD. One such early 
biomarker of eventual AD onset is low cerebral metabolic rates for glucose (CMRglc). 
APOE, the strongest genetic risk factor for late-onset AD, is now recognized as a 
strong modulator of cerebral metabolism, with Ε4+ individuals demonstrating metabolic 
alterations congruent with AD patients (4). Even cognitively normal Ε4 carriers 
demonstrate this pattern of glucose hypometabolism, thereby lending support to decreased 
CMRglc being an inherent biological feature of Ε4, rather than simply a byproduct of 
dementia (102-104). Importantly, these metabolic deficits are present decades in advance 
of AD onset in Ε4+ individuals, evidenced by reductions in CMRglc observed as early as 
their 20s (3). While lower CMRglc is measurable in young Ε4 carriers, a need exists for 
identification of other measurable metabolic alterations associated with APOE and glucose 
metabolism. Impairments in systemic metabolism are also strongly inversely correlated 
with CMRglc (105), suggesting that peripheral and brain metabolism are tightly coupled. 
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Thus, we hypothesized that whole body energy expenditure (EE) may be a measurable 
metabolic biomarker of young Ε4 carriers. 
We used IC to assess EE in young and middle-aged volunteers with and without 
the Ε4 allele to test for potential prodromal effects of APOE on metabolism.  While using 
IC for metabolic studies is common in clinical settings and exercise studies (106, 107), to 
our knowledge the method has not been previously applied to investigate biomarkers of 
cognitive impairment. Thus, repurposing IC to study the metabolic effects of an AD risk 
factor such as Ε4 represents a mobile, simple, and cost-effective new approach. To our 
knowledge, only two other studies have attempted to utilize IC to quantify the contribution 
of cerebral activation (i.e. a mental task) to whole body metabolic measures (108, 109). 
While we did not observe an APOE effect on IC measures during the cognitive challenge, 
we did find that IC is a sensitive tool to evaluate metabolic changes due to mental stress, 
as all participants showed a significant increase in EE. These results support claims that 
the brain consumes ~20% of EE despite only accounting for ~2% of body mass (110). 
Although resting EE was significantly lower in E4 carriers at rest, the most striking 
effect of APOE was observed after participants underwent a dietary carbohydrate 
challenge. There, E4+ individuals failed to increase VO2, leading to a significantly lower 
EE compared to non-carriers. In order to study the effect of a long-term high carbohydrate 
challenge, as well as test the utility of a human APOE mouse model, we fed E3 and E4 
mice a high carbohydrate diet (HCD). An E4-associated decrease in EE observed on a 
normal chow was exacerbated over the course of the HCD. Previous studies have shown 
differences in substrate utilization in these mouse models of human APOE (54, 111), and 
our findings now suggest that a HCD exaggerates E4 differences in EE.  
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Current understanding supports a triad of primary risk factors for the development 
of late-onset AD: old-age, E4, and female sex. Female study participants that were E4 
carriers showed significant decreases in energy expenditure at rest and after the glucose 
challenge. Studies have shown that females are at a greater risk for developing AD, as 60% 
of AD patients are female (60, 112). Female E4 carriers are also more likely to develop 
AD than male E4 carriers (63) and show increased neuropathology (113). Sex specific E4 
effects have also been observed in healthy older adults - female E4 carriers displayed 
greater CSF tau levels than female E4 non-carriers, a finding not observed in males (114). 
Here, we observed metabolic signatures in female E4 carriers that were different from 
female non-carriers decades prior to cognitive impairment, supporting a synergism of E4 
and female sex which increases AD risk.  
Aerobic glycolysis refers to the metabolism of glucose to lactate instead of the 
oxidative TCA cycle, despite the presence of abundant oxygen. This paradoxical 
phenomenon occurs in young individuals with a peak around five years of age, when 30% 
of the brain’s glucose is processed anaerobically and then steadily declines with age (115). 
Aerobic glycolysis in the brain appears to be cell and region specific, with astrocytes 
playing a major role in certain regions such as the dorsolateral prefrontal cortex, precuneus, 
and the posterior cingulate cortex (116). Importantly, areas associated with aerobic 
glycolysis also overlap with areas known to accumulate amyloid β, indicating that the 
anaerobic metabolism of certain brain regions may possibly predict amyloid burden in later 
life (117). Furthermore, a recent large-scale proteomics study implicated proteins involved 
in glial sugar metabolism as most significantly associated with AD pathology and cognitive 
impairment (118), while another showed rates of aerobic glycolysis in preclinical AD 
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predict higher tau deposition (119). Here, we observed that Ε4 carriers exhibit a 
bioenergetic profile consistent with an active aerobic glycolysis phenotype. When we 
performed metabolic pathway and enrichment analyses on plasma metabolites extracted 
from Ε4 carriers and non-carriers, the most significant pathways altered were “glycolysis” 
and “Warburg effect”, respectively, while the most significantly increased metabolite in 
E4 subjects was lactate. Together, these changes in the plasma metabolome of young and 
middle aged E4 carriers point to a role for APOE in regulating aerobic glycolysis. 
Using metabolic assays and stable isotope-resolved metabolomics in vivo and in 
vitro, we identified an Ε4-associated bioenergetic phenotype of impaired glucose oxidation 
and increased glycolysis which promotes lactate production. These results are congruent 
with other Ε4 and AD studies. For example, a recent study demonstrated that Ε4 astrocytes 
have increased lactate production (120), and neurons expressing Ε4 exhibit increased 
reliance on glycolysis for ATP production with apparent deficits in mitochondrial 
respiration (121). Fibroblasts from AD patients also show a Warburg-type shift from 
oxidative phosphorylation to glycolysis with increased lactate production (122). The 
potential mechanism underlying how AD and/or Ε4 alters metabolic efficiency to induce 
these effects is unclear. It has been proposed that Ε4 directly causes mitochondrial 
dysfunction, which is a known metabolic derangement of AD (123). Ε4 has been shown to 
reduce mitochondrial membrane potential by directly binding to complexes involved in 
oxidative phosphorylation and decreasing their activity (124). Treating naïve fibroblasts 
with astrocyte conditioned media from the same immortalized E3 and Ε4-expressing 
astrocytes we used here induced a decrease in OCR in tandem with an increase in lipid 
synthesis and lipid droplet formation (125). We have also observed this increased lipid 
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droplet formation in Ε4 astrocytes (126), as have others (127). A seminal study on lipid 
droplets in the brain found that lipid droplet accumulation in glia is APOE-dependent and 
directly linked to neurodegeneration and lactate transport (128). The intriguing link 
between increased lactate and increased lipid droplets in Ε4 glia remains to be fully 
elucidated.   
Interestingly, recent evidence has shown that lactate is an energy substrate used by 
the brain (129) and a competitive glucose alternative (130-132). Lactate has also been 
shown to decrease FDG-PET signal (133). An increase in astrocyte-derived lactate in Ε4 
carriers may compete with glucose as a substrate for brain metabolism and decrease 
CMRglc. Further, an increase in aerobic glycolysis might also act to lower energy 
expenditure, as glycolysis produces only 2 moles of ATP compared to the 34 moles of ATP 
from a mole of glucose metabolized via mitochondrial oxidative phosphorylation. This 
balance of anaerobic glycolysis versus oxidative phosphorylation behaves reciprocally 
(134). Increased mitochondrial ATP production downregulates glycolysis, while glycolytic 
ATP synthesis can suppress aerobic respiration (135). Given our findings of lower O2 
consumption and increased production of lactate, we speculate that E4 carriers have lower 
EE due to glycolysis being less energetically costly than downstream pathways.  
Our study has several limitations. As a primary goal was to assess individual 
metabolic responses to glucose, we performed blood draws immediately prior and 
immediately after the glucose challenge. It may be possible that mental stress during the 
cognitive challenge (which occurred prior to the first blood draw) altered the plasma 
metabolome beyond the normal resting state. We did however provide time after 
completion of the cognitive test for a “post-cog” rest in which participants were asked to 
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relax and breathe normally, similar to the initial rest period. Another potential confounder 
is that we provided glucose in the form of a sugary milk drink for the glucose challenge. 
While we used 50g of sugar based on clinical guidelines for glucose challenges (136), milk 
also includes fats and proteins. However, the high relative content of carbohydrates to other 
macronutrients ensures that any observed response (particularly at the ~30 minute time 
point analyzed) can be primarily attributed to carbohydrate metabolism. Indeed, the 
pathways most altered by the glucose challenge included galactose metabolism, starch and 
sucrose metabolism, and glycolysis. Finally, while we found E2 to be associated with lower 
plasma lactate and higher EE relative to non-E2 carriers, the study did not include any  
homozygous E2 carriers and the low overall allele frequency makes interpretation 
challenging. Still, these results are intriguing based on E2 being a known protective allele 
for AD (59, 61), and further study of energy expenditure and glucose metabolism in E2 
carriers is warranted. 
Using primary astrocytes, humanized mouse models, and cognitively unimpaired 
humans, we demonstrate decreased energy expenditure in young E4+ individuals. This 
phenomenon was sex-specific, exaggerated following a dietary glucose challenge, and 
reflected in a decreased rate of glucose oxidation in preference for aerobic glycolysis. 
While many questions remain, our study highlights novel roles for APOE and sex in 
modulating systemic glucose metabolism and provides a feasible method to assess APOE-
dependent metabolic signatures in pre-symptomatic young individuals. These findings 
provide important insights that may help to define dietary and pharmacological approaches 





Figure 2.1  Female Ε4 carriers show lower resting energy expenditure and lower thermic 
effect of feeding after a glucose challenge.    
(A) Experimental design of study. Individual components of energy expenditure were 
assessed in three distinct periods. Resting energy expenditure (REE) was assessed during 
the resting period. Cognitive energy expenditure (CEE) was assessed during the cognitive 
challenge and defined as difference in the area under the curve (AUC) of energy 
expenditure (EE) during the cognitive challenge and the AUC of EE from the resting period. 
Thermic effect of feeding (TEF) was assessed during the glucose challenge and calculated 
as the difference in AUC of EE during the glucose challenge and AUC of REE. (B) APOE 
genotypes of subjects represented in the study (E4- n=61, E4+ n=33; E2/E4 n=2, E2/E3 
n=10, E3/E3 n=51, E3/E4 n=28, E4/E4 n=3). (C) Correlation of average REE with 
participant age (Pearson correlation R2=0.11, **P<0.01, n=94). (D) Correlation of average 
REE and participant age separated by Ε4 carriers (purple) and non-carriers (blue) (Ε4- 
R2=0.233, ****P<0.0001; Ε4+ R2 =0.0042, P=0.719, E4- n=61 and E4+ n=33). Shaded 
areas refer to 95% confidence intervals. (E) Average REE for all, young, and middle-age 
E4- (n=44, 33, and 11 respectively) and E4+ females (n=27, 20, and 7 respectively) 
(*P<0.05, **P<0.01, unpaired t-test, two-tailed). (F) Average EE between resting and 
cognitive test periods in young (n=71) and middle-aged (n=23) participants. (***P<0.001, 
paired t-test, two-tailed). (G) CEE for all female participants and for the two age cohorts. 
(H) Average EE between resting and glucose challenge periods in young and middle-aged 
participants (***P<0.001, paired t-test, two-tailed). (I) TEF for all females and for the two 





Figure 2.2 Female Ε4 carriers show lower energy expenditure and lower oxygen 
consumption after a glucose drink. 
(A) Energy expenditure (EE) of female Ε4 carriers (purple) and Ε4 non-carriers (blue) 
during the glucose challenge. Values shown are means (lines) +/- SEM (shaded). (E4- 
n=44, E4+ n=27; *P<0.05, Two-way ANOVA repeated measures) (B) Incremental area 
under the curve (AUC) of EE was determined by Ε4 carriage and further by respective 
APOE genotypes in all participants. (E4- n=61, E4+ n=33; E2/E4 n=2, E2/E3 n=10, E3/E3 
n=51, E3/E4 n=28, E4/E4 n=3; **P<0.01, unpaired t-test, two-tailed; #P<0.05 One-way 
ANOVA,) (C) Time course of average VCO2 values of Ε4- and Ε4+ females during the 
glucose challenge period. Dashed lines refer to linear regression result. (D) AUC of VCO2 
for all participants. (E) Time course of average female VO2 during glucose challenge. 
(*P<0.05, Two-way ANOVA repeated measures) (F) AUC of VO2 for all participants 






Figure 2.3 Targeted metabolomics reveals lactate as a differentially regulated metabolite 
in E4+ plasma. 
(A,D) Pathway impact analysis highlights pyruvate metabolism and glycolysis as pathways 
significantly altered by E4 carriage in human plasma at baseline (A), while multiple 
carbohydrate and lipid processing pathways are altered by E4 carriage following the 
glucose drink (D) (FDR <0.01). (B,E) Volcano plots showing changes in plasma 
metabolites. Lactate was the most significantly altered metabolite by APOE genotype at 
baseline (B), while multiple metabolites differed post-glucose drink (E) (ANOVA, FDR 
<0.05). (C) Lactate values in individual subjects as determined by GC-MS analysis. (F) 
Enrichment analysis highlights multiple metabolic pathways as significantly altered by E4 
carriage following the glucose drink, including the top hit of ‘Warburg effect’. All 
comparisons are E4+ (n=33) vs E4- (n=61); A-B, denote analysis of pre-glucose drink 




Figure 2.4 E4 mice show lower energy expenditure that is exacerbated by a high 
carbohydrate diet.  
E3 and E4 mice were housed individually for 48 hours with ad libitum access to normal 
chow (A) or a high carbohydrate diet (HCD) (B). Dark cycles are indicated in grey with 
light cycles in white. Light cycles were used for calculating averages of energy 
expenditure, VCO2 and VO2 (shown to the right) (***P<0.0001, ****P<0.00001, unpaired 
t-test, two-tailed; E3 n=13, E4 n = 20). Violin plot values represent means (black dashed 
line) and upper and lower quartiles (gray dotted line). 
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Figure 2.5 Stable isotope resolved metabolomics reveals increased lactate synthesis and 
decreased entry into TCA cycle in E4 brains and astrocytes. 
(A) Experimental design (13C, blue filled circles; 12C, white circles; (m+n, where n is the 
number of 13C labeled carbons within a metabolite). (B) [U-13C] glucose was administered 
in vivo to E3 (n=6) and E4 (n=8) mice via oral gavage, brain tissue was collected after 2 
hours, and metabolites analyzed for 13C enrichment in pyruvate and lactate. While fully 
labeled pyruvate is present in similar amounts in E3 and E4 brains, lactate synthesized from 
13C-glucose is higher in E4 mouse brains (C) LDH activity is higher in E4 brains as 
estimated by the ratio of lactate (m+3) / pyruvate (m+3), while glucose entry into the TCA 
cycle via pyruvate dehydrogenase is decreased in E4 brains as estimated by the citrate 
(m+2) / pyruvate (m+3) ratio. (D) E3 and E4 expressing astrocytes were cultured in [U-
13C] glucose media for 24 hours, media collected, cells washed, and metabolites analyzed 
for 13C enrichment (n=6). Primary astrocytes expressing E4 show increased 13C enrichment 
in lactate, (E) higher LDH activity (F) and decreased 13C enrichment in the TCA cycle 
(average of all detected TCA intermediates) (G-H) Increased lactate synthesis as measured 
by HSQCAD NMR spectroscopy (n=3). Representative NMR spectra (I) showing E4 





Figure 2.6 E4 astrocytes show increased glycolysis and lower oxidative respiration. 
(A) Extracellular acidification rate (ECAR) of E3 and E4 primary astrocytes shown over 
time during the glycolysis stress test (n=24 for both groups). (B) Contributions to ECAR 
at baseline, in response to glucose (glycolysis), in response to stress (glycolytic capacity), 
and un-tapped reserve were calculated and shown. (*P<0.05, ***P<0.001, Unpaired t-test, 
two tailed) Values represent means +/- SEM. (C) Oxygen consumption rate (OCR) during 
the glycolysis stress test assay was graphed over time and (D) represented as average 
respiration before and after glucose (***P<0.001, ****P<0.0001, unpaired t-test, two 
tailed). Values represent means +/- SEM. (E) Metabolic phenotypes of E3 and E4 
astrocytes were characterized by plotting ECAR vs. OCR. (F) E3 and E4 astrocytes were 
incubated in glucose free media (-) or glucose rich media (+) and oxidation of 1.0 µCi/mL 
14C-glucose was measured by trapping 14CO2 and counting radio activity. (*P<0.05 
unpaired t-test, two-tailed, n=4 per genotype) Values represent means of percentages of 
E3. (G) Glucose oxidation capacity, dependency, and flexibility was assessed in E3 and 
E4 astrocytes via the Mito Fuel Flex Assay. (*P<0.05 Two-way ANOVA, Sidak’s multiple 
comparisons test) Values represent means +/- SEM. (H) E3 and E4 astrocytes were 
incubated in 1.0 µCi/mL 14C-glucose with (+) or without (-) 12.5mM lactate (*P<0.05, 
unpaired t-test, two-tailed, n=3 per genotype). Values represent mean of percent change 





Table 2.1 Age, sex, and APOE genotype of cognitively normal individuals according to Ε4 
carriage and age cohort (young=18-39, middle-aged=40-65).  















Age Sex (N) APOE Genotype (N) 
Average Age 
(SD) 

















13 33 8 38 0 0 0 
Ε4 Carriers (E4+) 
25.84 
(6.08) 







4 11 2 13 0 0 0 
Ε4 Carriers (E4+) 
55.5 
(8.78) 
1 7 0 0 0 7 1 
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Table 2.2 Clinical characteristics of cognitively unimpaired individuals according to Ε4 
carriage and age cohort (young=18-39, middle-aged=40-65).  
Values represent means +/- (SD). Ca, Caucasian; AA, African American; His, Hispanic; 
A, Asian; BMI, body mass index. 
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CHAPTER 3. LIPID DROPLETS IN NEURODEGENERATIVE DISORDERS 
[This chapter consists of material adapted from an accepted manuscript: Farmer BC, Walsh 
AE, Kluemper JC, Johnson LA. Lipid Droplets in Neurodegenerative Disorders. Frontiers 
in Neuroscience. Accepted June 23, 2020. doi: 10.3389/fnins.2020.00742.] 
3.1 Introduction 
Lipid droplets (LDs) are spherical organelles that store intracellular neutral lipid such 
as triacylglycerols (TAGs) and cholesteryl esters (CEs) (137, 138). LDs serve as lipid 
reservoirs for cells by providing substrates for membrane formation and energy metabolism 
(139). Adipose tissue is the most LD-enriched tissue in the body, where fatty acids are 
stored in times of nutrient excess and then mobilized with increased energy demand (140). 
LDs also affect physiological processes in the periphery beyond simple fatty acid storage 
and supply, such as in inflammation and insulin signaling. For example, LDs in various 
immune cell types contain a large pool of intracellular arachidonic acid (AA), which 
provides a reserve of precursors for eicosanoid synthesis (141-143) Enzymes involved in 
AA processing have been demonstrated to LDs, indicating that these organelles serve as a 
supply site for inflammation (144). Additionally, LDs have been linked to peripheral 
metabolic dysfunction such as ectopic lipid accumulation (145) and insulin resistance 
(146). Overexpression of LD-associated proteins such as Cidea increase fat accumulation 
in mice, and human expression of LD proteins in adipose correlates with clinical insulin 
resistance (147). These studies therefore suggest a role for LDs in obesity-driven metabolic 
dysregulation. 
Lipid droplets may also affect cellular physiology and function in the central nervous 
system (CNS). The brain is the second most lipid-rich organ (148), storing 20% of the 
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body’s total cholesterol (149). Alteration in the lipid composition of CNS cells has been 
shown to affect cell function and normal neural activity (150, 151). Notably, 
neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease 
(PD), share lipid dysregulation as a metabolic feature in disease pathology. In this review, 
we discuss evolving knowledge and recent advances in understanding the contribution of 
LDs to pathogenesis of neurodegenerative diseases. Growing knowledge of LDs in the 
central nervous system is important to the advancement of the field, as these dynamic 
organelles may reveal common mechanisms and potential therapeutic targets to 
neurodegenerative disease.  
 
3.2 LD structure, composition, and biogenesis 
Hydrophobic molecules such as TAGs, CEs, and retinyl esters constitute the core of 
a lipid droplet (152), while the outer surface is formed by an amphipathic lipid monolayer 
embedded with LD-associated proteins. (The general structure of an LD is illustrated in 
Figure 3.1). Additionally, proteins can reside in the LD core depending on the cell type. 
This unique monolayer distinguishes LDs from organelles of similar size, such as 
lysosomes and endosomes, as the latter exhibit a lipid bilayer. Of the many LD-associated 
proteins, members of the perilipin family have been well described for their essential roles 
in LD metabolic regulation (153). The exterior protein components of LDs allow for a 
variety of unique interactions that may explain the myriad of cellular roles accomplished 
via LDs in energy homeostasis, cellular communication, and disease.  
Lipid droplets arise from the endoplasmic reticulum (ER) by budding off the 
cytoplasmic leaflet of the ER membrane (154). They are comprised of acyl-glycerols that 
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are synthesized through the action of diacylglycerol transferases (DGATs), which convert 
acyl-CoA-bound fatty acids and diacylglycerols (DAGs) into the TAGs that fill the LD 
core (155). Cholesterol acyltransferases synthesize CEs which are also incorporated into 
the core of nascent LDs (156). Once separated from the ER membrane, LDs may continue 
to grow via LD fusion and further TAG incorporation. Fusion of LDs with the aid of 
members of Cell death-inducing DFF45-like effector (CIDE) family proteins (157) 
coalesce smaller LDs into larger LDs. Re-localization of TAG synthesis enzymes like 
DGAT2 and GPAT4 from the ER to the LD surface allows direct synthesis of TAGs from 
cellular lipid sources (158), such as fatty acids derived from autophagic phospholipid 
breakdown (159). The incorporation of cellular debris into LDs is commonly seen during 
periods of stress and starvation and are thought to protect the cells from lipotoxicity (160). 
LDs exhibit a variety of protein and lipid signatures, and these various compositions can 
help determine LD localization and utilization. For example, perilipin 2 (PLIN2) has 
relatively low control over lipolysis, so LDs that contain PLIN2 may be more easily broken 
down. Conversely, PLIN1 and PLIN5 actively promote lipolysis when activated. PLIN1 
acts through its release of CGI-58, a co-activator of adipose triglyceride lipase (ATGL) 
(161), while PLIN5 binds directly to ATGL to promote lipolysis (162). Therefore, LDs 
with varying PLIN proteins will behave differently across various tissues and 
environmental conditions (153). 
Lipid homeostasis is necessary for maintaining neuronal function and synaptic 
plasticity (163), and dynamic interaction between perilipins and lipases on the LD surface 
regulate cellular lipid storage, breakdown, and metabolism (164). In most cells, the bulk of 
LD breakdown is accomplished through ATGL, another LD outer layer protein (165). 
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Lipophagy is also a recognized LD breakdown process, in which an LD is taken up into an 
autophagosome and subsequently fuses with a lysosome to breakdown LD contents mainly 
through lipid acid lipases (166). During times of metabolic stress, lipases cleave 
triglycerides into FAs, which are then processed in the mitochondria to liberate the energy 
stored in droplets via beta-oxidation into acetyl-CoA and subsequent TCA cycle activity 
and oxidative phosphorylation (167). LDs have been shown to provide energy substrates 
(126, 168), lipid signaling molecules (169), and membrane infrastructure materials (170) 
for various cell types.  
3.3 LD formation in cells of the brain 
Essentially all brain cell types have been shown to form LDs (Table 3.1 and Figure 
3.2). A recent study claimed that the majority of brain LDs (stained with the fluorescent 
neutral lipid probe BODIPY) were co-localized with ionized calcium binding adaptor 
molecule 1 (Iba1), a microglia/macrophage-specific protein. This finding implicates 
microglia as a main harbor of LDs (171). These lipid-associated microglia had a unique 
transcriptomic signature compared to non-LD-laden microglia, suggesting that LDs in 
microglia are either a cause or result of substantial transcriptional modulations. However, 
subsequent co-localization using other brain cell-specific markers was not reported in this 
study, leaving the door open for other cell types to be involved. For example, ependymal 
cells that line the cerebral ventricular system have been shown to accumulate LDs, along 
with Glial fibrillary acidic protein (GFAP) positive cells that are closely associated in the 
ependymal niche (GFAP is a common marker for astrocytes and ependymal cells) (172). 
Lesions to the CNS have also induced LDs in neurons and astrocytes (173), and glial cells 
have been shown to form LDs from phagocytosed myelin fragments (174). Finally, a 
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thorough immunofluorescence study examining cell types that harbor PLIN positive 
droplets found Iba1+, GFAP+, NeuN+ (a neuron specific antibody), and S100+ (a 
calcium binding protein that is localized in astrocytes) to colocalize with droplets (175). 
Together, these studies and others demonstrate that multiple cell types in the brain are 
capable of forming LDs. 
3.4 Anatomic structures associated with LDs in the brain 
The subventricular zone (SVZ) has surfaced as a key region for lipid droplets in the 
brain. The SVZ lines the wall of the lateral ventricles and is composed of neural stem cells 
that are capable of differentiating into various CNS lineages (176). This highly active and 
heterogeneous cellular region is an energetically needy zone, and it is reasonable to expect 
ample energy stores are on board in order to meet its energetic needs (177). It was first 
shown that large LDs were found in the ependyma of the SVZ (178). This was 
accomplished using an electron microscopy approach that detailed the associations of 
various SVZ cell types with confirmatory immunostaining.  
Another group found that the LD lipase ATGL, which is encoded by the patatin-like 
phospholipase domain-containing protein 2 (PNPLA2) gene, is highly active in the SVZ 
and choroid plexus. Furthermore, mutating PNPLA2 led to a significant increase in LD 
formation in both areas (165). This study was the first to report a function of PNPLA2 in 
the brain and describe its regional role in maintaining cerebral lipid metabolism. 
Additionally, knock out of the GTPase regulator associated with focal adhesion kinase-1 
(GRAF1) induced LDs in the brains of post- natal day seven pups (179). Apart from studies 
of LDs in the brain arising from genetic alterations, it was found that LDs accumulate in 
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the SVZ progressively with age; 12-month-old mice showed a nearly two-fold increase in 
LDs in the SVZ compared to 3-month-old mice (180).  
The SVZ has also been shown to harbor LDs in the context of Alzheimer’s disease 
(AD). Hamilton and colleagues showed that both an AD mouse model and AD human post-
mortem tissue accumulate LDs along the lateral ventricle (181). Using tandem mass 
spectrometry, the LD contents were identified, revealing high concentrations of oleic acid-
enriched TAGs (181). Interestingly, direct infusion of oleic acid into the lateral ventricle 
was sufficient to induce LD formation along the SVZ, but insufficient to impair 
neurogenesis (181). Another group found the choroid plexus to have more LDs as AD 
progressed in human post mortem tissue (182). Further studies are needed to clarify the 
role of LDs in the SVZ in normal aging and neurodegeneration. 
Although the SVZ is the most extensively studied brain region with regards to LD 
formation, other structures such as the frontal cortex, hippocampus, olfactory bulbs, and 
hypothalamus have been shown to accumulate LDs (Table 3.1). In fact, prior studies on 
the hypothalamus indicate that LDs may affect certain processes such as satiety (183). In 
this study, Kaushik demonstrates that autophagy during starvation leads to the mobilization 
of neuronal lipids which can then increase food intake though the upregulation of agouti-
regulated peptide. This is just one of many studies which explore the wide variety of brain 




3.5 What causes lipid droplets to form in the brain? 
3.5.1 Aging 
Lipid droplets appear to accumulate in the brain during the normal process of aging. 
For example, analysis of microglia from 20-month-old mice revealed an abundance of 
BODIPY+ cells in comparison to a matched 3-month-old cohort (171). Analyses of human 
tissue (postmortem) also revealed that PLIN2+ Iba1+ microglia were more frequent in an 
aged (67-years-old) individual than in a young (22-years-old) individual (171). A 
significant increase in LDs has also been observed in the pia mater, cortex, and striatum in 
18-month-old mice as compared to middle aged mice (175). Furthermore, an electron 
microscopy analysis of the basement membrane of the blood brain barrier (BBB) in 6-
month-old versus 24-month-old mice showed an age-dependent accumulation of LDs 
which caused significant thickening of the basement membrane (184). On the contrary, 
LDs are more commonly found in perivascular cells in middle age and then seem to shift 
toward the parenchyma in old age (175). Given these findings, age appears to regulate LD 
accumulation and regional deposition.  
 
3.5.2 Inflammation 
From in vitro studies of LDs to ex vivo brain imaging, inflammation has repeatedly 
been associated with LD formation as both a cause and as an effect (143). 
Lipopolysaccharide (LPS), a commonly employed pro-inflammatory stimulus, has been 
shown to increase the number and size of LDs in microglia (185). PLIN2 was shown to 
colocalize with these droplets, providing more evidence that PLIN2 is an LD-associated 
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protein that can be considered a marker for both LDs and inflammation in the brain. This 
was repeated recently in microglia-derived BV2 cells and expanded into an in vivo model 
of LPS treatment. That study by Marschallinger and colleagues found that more microglia 
contained LDs in LPS treated mice when compared to non-treated controls (171). To assess 
how the vasculature might affect LDs in the brain, Lee and colleagues i.v. infused 
triglyceride-rich lipoproteins (TGRL) and lipoprotein lipase into mice and found increased 
BBB permeability, therefore indicating that hyperlipidemia may increase lipid spill-over 
into the brain. To test how this treatment affected resident brain cells, they treated normal 
human astrocytes with the TGRL lipolysis products and found increased LD formation 
(186). Another study found that palmitate treatment of isolated primary astrocytes 
increased inflammatory markers including TNF-alpha, IL-1 beta, IL-6, and MCP-1 in 
addition to Oil Red O (a fat-soluble dye) staining and PLIN1 and PLIN2 transcription. 
Interestingly, treatment of microglia with conditioned media from lipid-loaded astrocytes 
enhanced microglial chemotaxis through a CCR2-MCP1 mechanism (187). These data 
suggest that LD-associated astrocyte inflammation may subsequently signal to microglia 
to augment the inflammatory response. However, it remains to be seen whether 
inflammation causes LDs, LDs cause inflammation, or both.  
 
3.5.3 Oxidative Stress 
Intracellular reactive oxygen species (ROS), as well as ectopic treatment with 
oxidative stressors such as hydrogen peroxide, induce LD formation in various cell types 
in the periphery (188-190). Similarly, increased oxidative stress in the brain appears to 
drive LD accumulation in a cell-specific manner. For example, neuronal hyperactivity from 
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trauma or chemogenetic activation increases glial LD accumulation (173). These LD-laden 
glia upregulate genes to neutralize the peroxidated lipids generated by activated neurons. 
Astrocytes in particular appear to be uniquely suited for ROS management due at least in 
part to fatty acid binding protein 7 expression (191). Liu and colleagues first proposed this 
neuron-astrocyte metabolic coupling model in which neurons under stress export oxidized 
lipids to astrocytes as a means of neuroprotection (128, 192). LDs in glia may then be 
viewed as indirect indicators of neuronal damage from oxidative stress. Protective LD 
formation in glia has also been observed in the SVZ niche, where glia protect neuroblasts 
from peroxidation and thereby promote neural stem cell proliferation (193). Therefore, 
oxidative stress appears to be a driver of LD formation in the brain both under formative 
physiological processes during neuronal development, as well as in diseases associated 
with increased neuronal oxidative stress.  
 
3.6 What neurodegenerative disorders have been linked to lipid droplets? 
3.6.1 Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron 
disease (194). ALS is characterized by the progressive degradation of motor neurons in the 
CNS, leading to the inability to both initiate and control muscle movement. In addition to 
genetic mutations, altered metabolic function in ALS has been observed in cellular 
processes implicated in ALS pathology such as cell stress and energy homeostasis (195).  
Recent studies interested in lipid metabolism have shed light on connections 
between LDs and ALS pathology (196). For example, it is known that mutations in the 
human VAMP-associated protein B (hVAPB) cause ALS, although the disease-causing 
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mechanism itself remains unclear (197). Sanhueza and colleagues performed a genome-
wide screen in Drosophila to identify pathways involved in hVAPB-induced neurotoxicity 
and found that the list of modifiers was mostly enriched for proteins linked to LD dynamics. 
One modifier highlighted in this study was acyl-CoA synthetase long-chain (Acsl). Acsl 
promotes LD biogenesis and its downregulation reduces LD nucleation which decreases 
the size and number of mature LDs (198). Furthermore, another group showed that gain of 
function mutations in the LD protein seipin contributed to motor neuron disease symptoms 
in mice (197, 199). Together these studies suggest that impaired LD biogenesis may be an 
important pathological aspect to hVAPB-mediated ALS.  
A mutation that contributes to an early onset form of ALS occurs in the gene SPG11 
and affects lysosome recycling (200). Branchu and colleagues observed intracellular lipid 
accumulation followed by lipid clearance from lysosomes into droplets in wild-type (WT) 
mice. However, in Spg11 knockout mice, there was a significantly slower rate of lipid 
clearance and a decrease in LD size and number. Another study that implicates aberrant 
lysosomal function as a contributor to ALS reported that the C9orf72 gene plays a key role 
in metabolic flexibility in times of stress/starvation (201). They found that loss of C9orf72 
led to an increase in LDs, and that starvation-induced changes in lipid metabolism were 
mediated by coactivator-associated arginine methyltransferase (CARM-1). Since CARM-
1 regulates lysosomal function and lipid metabolism, these results suggest that the 
dysregulation of lipid metabolism, including the aberrant accumulation of LDs, could 
contribute to ALS pathology.  
Similar to studies linking LDs and peroxidation to Alzheimer’s disease, there also 
appears to be a connection between LDs and cellular stress in ALS. Bailey et al. showed 
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in Drosophila that ROS accumulation increased glial LD content, and that when glia were 
unable to produce LDs, neuroblasts experienced peroxidative damage (193). Additional 
work by Simpson et al. provided a link between LDs, peroxidation, and ALS by showing 
a positive correlation between lipid peroxidation markers in ALS patient cerebrospinal 
fluid and disease burden (202). Thus, LD dynamics may contribute to ALS, potentially 
through a mechanism in which glia are unable to protect neurons through normal lipid 
accumulation and storage mechanisms (196).  
 
3.6.2 Huntington’s Disease 
Huntington’s disease (HD) is a hereditary neurodegenerative disease caused by a 
mutation in the huntingtin gene (Htt) that then codes for the Htt protein (203). Mutant Htt 
contains an expanse of repeating glutamines at the N terminus, thus causing Htt 
oligomerization and aggregation that leads to neuronal death. A wide range of metabolic 
abnormalities characterizes HD, including alterations in autophagy (204). Martinez-
Vicente et al. found that macroautophagy is compromised in cellular and mouse HD 
models and in HD patient-derived tissues, as evidenced by the inability to recognize and 
properly sequester unneeded cellular components (205). Autophagosomes in HD models 
failed to recognize and load excess cargo, thus causing autophagic cytosolic components 
to have a slower turnover leading to toxic accumulation of lipid in cells. They also observed 
an increase in LD number and area in fibroblasts, hepatocytes, striatal cells, and primary 
neurons from a HD mouse model (Qhtt mice). Furthermore, striatal tissue from advanced-
stage HD patients had increased oil red O staining density when compared to age-matched 
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controls (205). The authors hypothesized that increased LD content in HD cells could be 
due to their reduced ability to recognize and degrade excess lipid by macroautophagy. 
Aditi and colleagues used transgenic Drosophila expressing the mutated form of 
human Htt in neurons to better understand HD energetics (206). They found that when 
compared to controls, diseased flies exhibited a characteristic pattern of weight change that 
is correlated with HD progression, as evidenced by altered lipid concentrations over time. 
Interestingly, and in contrast to the above study by Martinez-Vicente’s group, flies had 
high levels of lipid at disease onset and low levels at the terminal stage in neurons. This 
finding was also true for abdominal body fat cells, despite only expressing mutant Htt in 
neurons. LD size mirrored the overall lipid levels, with large LDs being found in 3-7-day-
old diseased adults and small lipid droplets forming by days 11-13 in diseased flies. These 
findings suggest that mutant Htt leads to dysregulated lipid metabolism in addition to 
neurodegeneration. However, further studies in both mammalian and fly models are needed 
to fully elucidate the role LDs may play in the onset of HD. 
 
3.6.3 Parkinson’s Disease 
Parkinson’s disease (PD) is caused by a loss of dopaminergic neurons and leads to 
abnormal brain activity and symptoms such as tremors, bradykinesia, and limb rigidity 
(207). Lewy bodies are pathological hallmarks of PD that are found in pre-synaptic 
terminals of neurons. These Lewy bodies contain aggregates of the α-synuclein protein 
which has been shown to accumulate on LD phospholipid surfaces, slowing lipolysis of 
LDs (208). Cole and colleagues also found that two mutant forms of α-synuclein, A30P 
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and A53T, showed decreased capacity to reduce LD turnover in neurons compared to WT 
α-synuclein. These results suggest LD turnover in neurons is contingent on proper α-
synuclein function, and that LD lipolysis may contribute to PD (208). However, these 
findings are complicated by the work of Outeiro and Lindquist, who found that both WT 
and A53T α-synuclein caused an accumulation of LDs in yeast, whereas A30P synuclein 
did not (209). These findings suggest that LDs may play a cell-specific role in PD 
pathology and call for further study in this area. 
Integrated genome wide association studies have found that key mechanisms of PD 
pathogenesis (oxidative stress response, lysosomal function, endoplasmic reticulum stress 
response and immune response) rely heavily on genes regulating lipid and lipoprotein 
signaling. For example, Klemann and colleagues found that lipid and lipoprotein signaling 
is regulated by the same processes involved in dopaminergic neuron death, and found 
deficient signaling to be associated with increased risk for PD (210). Scherzer et al. found 
that genes related to lipid metabolism and vesicle-mediated transport had the largest effects 
on increasing α-synuclein toxicity in yeast (211). This same group also classified a variety 
of genes related to α-synuclein expression in Drosophila, and again found that lipid-related 
genes were strongly associated with this process. The authors proposed that dysregulation 
in lipid processing may be an indicating factor of problems caused by A30P α-synuclein 
toxicity (212).  
Additional studies have begun to investigate lipid dyshomeostasis in PD more 
deeply. For example, suppression of the oleic acid generating enzyme stearoyl-CoA-
desaturase (SCD) was recently found to be protective against α-synuclein yeast toxicity, 
and SCD knockout models in roundworms was shown to prevent dopaminergic neuron 
56 
 
degeneration (213). Specific genes related to lipid regulation have also been identified. 
ATPase cation transporting protein 13A2 (ATP13A2) functions in cation transport within 
the cell. Mutations to ATP13A2 are associated with PD and overexpression of ATP13A2 
showed a decrease in various forms of lipids in vitro (214). When looking at these findings 
together, it is evident that LDs and lipid homeostasis play a more significant role in PD 
than originally thought. This line of thought is supported by Fanning et al., who stated that 
α-synuclein toxicity and cell trafficking defects have been associated with aberrations in 
LD content and distribution (215). PD has classically been believed to be a 
“proteinopathy”, but with many of the recent discoveries, lipid dyshomeostasis is rapidly 
becoming one of the fundamental characteristics of this disease (215). 
 
3.6.4 Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia worldwide (216). 
When Alois Alzheimer wrote his seminal paper in 1907 describing the case of Auguste 
Deter, he noted three neuropathological hallmarks. He found “striking changes of the 
neurofibrils” and “minute milliary foci caused by deposition of a particular substance in 
the cortex”. He also observed glial changes and stated, “many glia include adipose 
inclusions” (217, 218). While the first two findings have been studied extensively by 
scientists interested in the contribution of tau and amyloid to disease progression, the 
finding of glial lipid accumulation has largely been overlooked. It wasn’t until recently that 
this phenomenon of increased lipid accumulation in Alzheimer’s disease was revisited and 
examined. Hamilton et.al helped renew interest in this phenomenon in a report describing 
increased LD formation in the SVZ of both 3xTgAD mice and human AD samples which 
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correlated with defects in neurogenesis (181). Interestingly, acute administration of 
intracerebral oleic acid mimicked the LD phenotype of the 3xTgAD mice, but did not alter 
SVZ neuron viability, suggesting that disease-associated LD accumulation is not simply a 
result of environmental lipid exposure. Derk and colleagues found a highly significant 
increase in both neutral lipid and diaphanous 1 (DIAPH1) expression in myeloid cells in 
AD brains (219). DIAPH1 mediates signaling for the receptor for advanced glycation end 
products (RAGE), an inflammatory ROS-producing pathway. This apparent correlation 
between neutral lipid accumulation and inflammatory signaling suggests that LDs may be 
key players in cerebral inflammatory responses. A recent study further validated this 
model, where it was discovered that astrocytes uniquely upregulate ROS management 
genes, seemingly to manage the import of neuron-derived lipid oxidation products (173). 
This study showed that neuronal hyperactivity alone was sufficient to initiate neuronal lipid 
peroxidation, neuronal lipoprotein export, and subsequent management and storage of 
peroxidized lipid as LDs in astrocytes. Further work done by van der Kant and colleagues 
showed that CE, which can be incorporated into LD cores through normal LD biogenesis, 
increase the accumulation of phosphorylated tau (p-tau) by reducing proteasome activity 
(220). The study showed that both statins and an allosteric activator of cholesterol 24-
hydroxylase (efavirenz) helped lower p-tau levels in human neurons by reducing CE 
concentrations, thereby providing a potential mechanistic link between LDs and AD 
neuropathology.  
A role for apolipoproteins as shuttles for oxidative waste from neurons has been 
described in the brain (128). Additionally, different isoforms of Apolipoprotein E (ApoE) 
were shown to have altered efficiency for lipid shuttling. ApoE4-laden lipoproteins 
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appeared to be less efficacious at the delivery of lipotoxic products to glia than lipoproteins 
associated with ApoE3.  
This is particularly interesting in light of the E4 allele of APOE being the strongest 
genetic risk factor for the development of late onset AD. Our group recently showed that 
astrocytes expressing E4 preferentially accumulate and utilize LDs for energetic needs 
(126). Additionally, transcriptional profiling of glia derived from human iPSC lines 
harboring homozygous E4 or E3 alleles showed that the majority of differentially 
expressed genes in astrocyte-like cells involved lipid metabolism and transport (221). This 
group also found that a phenotype of E4 astrocytes included the accumulation of 
intracellular and extracellular cholesterol. They hypothesized that since cholesterol is 
responsible for a wide range of functions in the brain, altered cholesterol metabolism in E4 
glia may be associated with pathological phenotypes in neurodegenerative disorders. 
Conditioned media from E4 astrocytes has been shown to induce LDs in other cell types, 
suggesting that E4 may also act extracellularly to induce LD formation (125). Finally, 
neutral lipid staining of the choroid plexus in post-mortem AD brains proposed LDs as 
central hubs of an ApoE-mediated complement-cascade regulation (182). The authors 
found ApoE to bind to complement component 1q (C1q), a protein complex that binds 
antigen-antibody complexes, on LDs in the choroid plexus. Since C1q protein is involved 
in the activation of the classical complement pathway, this interaction effectively keeps the 
complement system of the immune system in check at the CNS/vasculature interface. 
While all ApoE isoforms showed equal binding affinity for C1q, post-mortem mice and 
human E4 brains were shown to accumulate LDs more abundantly. Interestingly, these 
lipid deposits significantly correlated with neuropathological staging of AD, pointing to 
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APOE regulation of the complement cascade at the choroid plexus niche as a novel 
hypothesis for AD pathogenesis.  
 
3.6.5 Hereditary Spastic Paraplegia 
Hereditary spastic paraplegia (HSP) is a group of inherited neurological disorders 
that cause muscle weakness and tightness, primarily in the legs, through the degeneration 
of long corticospinal axons (222, 223). Studies of HSP-causing proteins suggest a link 
between lipid metabolism and the development of disease. For example, DDH2 domain 
containing protein 2 (DDHD2) is a triglyceride hydrolase in the brain that is implicated in 
recessive complex HSP. The systemic genetic knockout and pharmacological inhibition of 
DDH2 resulted in large-scale accumulation of LDs within the CNS, but not elsewhere 
(224). These data indicate a link to TAG metabolism, as the inhibition of DDHD2 affects 
lipid homeostasis and LD number.  
One of the most common genetic mutations involved in HSP occurs in the 
microtubule severing protein spastin (200, 225) . The M1 isoform of spastin contains a LD 
targeting sequence which contributes to protein targeting to LDs and LD sorting at the ER. 
Additionally, spastin deficiency in Drosophila and C.elegans altered LD number and TAG 
content. This study suggests that LD processing may contribute to the pathogenesis of HSP 
(225). Additionally, a study by Arrabit et al. further identifies spastin as a regulator of LD 
dispersion and dynamics. This group showed that mutations in the spastin M1 isoform 
induced ER reorganization in HeLa cells. This reorganization subsequently disrupted 
spastin’s ability to disperse LDs throughout the cell and aberrantly modulated neutral lipids 
and phospholipids on membranes throughout the muscle and brain (226). Furthermore, 
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embryonic zebrafish cells that were treated with oleic acid (a common method to induce 
LD formation) indicated that a loss of spastin resulted in a higher number of smaller LDs, 
therefore suggesting differential generation and/or dispersion of LDs (226). In addition to 
identifying potential new HSP biomarkers, this study also proposes that HSP-causing 
mutations impacts lipid profiles and LD networks.  
Several groups have also forged a connection between the protein spartin and LD 
regulation. Spartin is a multi-functional unit that associates with LD, and a lack of spartin 
expression contributes to a HSP form called Troyer syndrome (227). In one study by 
Edwards et al., spartin surrounded LD clusters in oleic acid treated HeLa cells, thus 
suggesting that spartin is recruited to LDs (228). Additionally, in spartin knockout mice, 
female mice had increased LDs number and higher perilipin protein levels in adipose tissue 
(229). Hooper and colleagues further demonstrated an interaction between spartin and LDs. 
Their experiments in HeLa cells showed that spartin binds to and recruits the ubiquitin 
ligase atrophin-1-interacting protein 4 (AIP4) to LD. This interaction subsequently 
promotes the ubiquitination of PLIN2. Since PLIN2 resides on LD membranes and 
regulates TAG turnover, spartin may play a role in LD regulation in cells and contribute to 
Troyer syndrome pathology (227). Furthermore, another group reported binding 
interactions between spartin and protein kinase C interacting proteins (ZIPs) at the surface 
of LDs. Spartin-expressing HEK-293 cells exhibit co-localization of spartin with ZIP1 and 
ZIP3 on LDs as shown by superimposition of spartin GFP-tagged fluorescence and Oil Red 
O fluorescence. (230). Interestingly, in the absence of spartin, no ZIP proteins were 
detected on the LD surface (230). These collective findings suggest that impaired LD 
metabolism might be one mechanism that contributes to Troyer Syndrome. 
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3.7 Regulation of LDs in the brain 
Lipid droplets in the brain may be regulated differently than more traditional LD 
niches. DDHD2 action in HSP implicates this protein as an important player in CNS lipid 
metabolism but also shows a dichotomy between peripheral LDs and central LDs. The 
BBB forms a tight and regulated gate for lipid import and export into the brain, and thus 
there are separate pools of lipids that constitute the intracellular LDs located in cells in the 
CNS versus the periphery. Lipid contents of the cell types that make up the BBB appear to 
regulate its permeability (184, 231). Since enzyme mutations of key lipases are manifested 
differently in the brain and given the existence of lipid-regulatory mechanisms between the 
periphery and the CNS, it is possible that the two pools are controlled by separate 
mechanisms. Investigators should be cautious when applying canonical peripheral LD 
pathways to brain LD biology until more evidence emerges for conserved physiological 
pathways between the brain and the periphery.  
Sex-specific regulation of lipid metabolism and LDs in the brain should also be 
considered. In one study, neurons of male rats were shown to be more vulnerable to 
starvation than neurons of female rats, with male neurons exhibiting decreased 
mitochondrial respiration, increased autophagosome formation, and increased cell death 
when compared to females (232). On the other hand, the same study showed that female 
tolerance of starvation conditions was associated with increases in fatty acid content and 
LD formation in order to prolong cell survival. These findings suggest that central LD 
dynamics may be sex dependent. Potential sex differences should be considered in future 
studies in order to better understand the contribution of sexually dimorphic features to 
cerebral LD metabolism and its relevance to disease susceptibility and pathology.  
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3.8 Future directions and concluding remarks 
Several important knowledge gaps remain in our understanding of the role of LD 
biology in the pathophysiology in neurodegenerative disease. One important future 
direction for the field is to better understand the full composition of lipids comprising brain 
LDs – in both healthy and diseased states. A clearer picture would likely be revealed by 
the precise distribution of lipid classes in distinct brain regions, as well as in specific 
neurodegenerative diseases. However, their relatively small size and the diversity of LDs 
by age, cell type, and disease type complicate the compilation of a lipid profile of LDs. 
Additionally, in vivo analysis of lipids in general is challenging, as they are a diverse class 
of macromolecules and are relatively insoluble (233). However, improved techniques in 
mass spectrometry provide new ways to document the lipid composition in LDs. For 
example, matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-
IMS) allows for anatomically-specific direct detection of lipids within membranes through 
the production of lipid-derived ions (234). Since MALDI can detect phospholipids, 
sphingolipids, and glycerolipids, this technique provides the opportunity for an in depth 
and spatially-resolved profile of LDs (235). The continued use of powerful imaging 
techniques such as MALDI will be important to providing a better understanding of lipid 
class distribution in cerebral LDs. 
LDs are cellular fuel stores, markers of inflammation, signaling hubs, protective 
waste reservoirs for hyperactive neurons, products of lysosomal dysregulation, and 
hallmarks of age. With such a wide array of roles, it is not surprising that LD accumulation 
has been linked to trauma, neurodegeneration, and aberrant cerebral metabolism. LDs are 
promising targets for novel investigations of neurological disease diagnosis and 
therapeutics. Therapeutic treatments could be targeted at restoring lipid balance, decreasing 
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droplet levels, or improving other aspects of lipid metabolic pathways. Further study on 
LDs and lipid metabolism will be essential in advancing our knowledge of cerebral 
metabolism, as well as the multifaceted etiologies of neurological disease. 
 
Table 3.1  Lipid droplet-related literature pertaining to the brain. These papers have been 
classified by the model organism that was used, area of the brain that was studied, and cell 
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GRAF1a was found on LDs in 
primary glial cells that were fed 
oleic acid. Overexpression of 
GRAF1a promoted LD clustering 
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LPS treated microglia accumulated 
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HeLa (208) 
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Cells treated with LPL 





Figure 3.1 A diagram of the molecular structure of a standard lipid droplet (LD) along with 
a software reconstruction of a microscopic image of astrocytes in vitro containing LDs 
































CHAPTER 4. APOE4 ALTERS FATTY ACID METABOLISM AND INCREASES 
LIPID DROPLET FORMATION IN ASTROCYTES 
[This chapter consists of material adapted from a published manuscript: Farmer BC, 
Kluemper JC, Johnson LA. Apolipoprotein E4 Alters Astrocyte Fatty Acid Metabolism 
and Lipid Droplet Formation. Cells. 2019 Feb. PMID: 30791549. For supplementary 
materials pertaining to this chapter, see appendix 1.] 
 
ABSTRACT 
Lipid droplets (LDs) serve as energy rich reservoirs and have been associated with 
apolipoprotein E (APOE) and neurodegeneration. The E4 allele of APOE (E4) is the 
strongest genetic risk factor for the development of late onset Alzheimer’s disease (AD). 
Since both E4 carriers and individuals with AD exhibit a state of cerebral lipid 
dyshomeostasis, we hypothesized that APOE may play a role in regulating LD metabolism. 
We found that astrocytes expressing E4 accumulate significantly more and smaller LDs 
compared to E3 astrocytes. Accordingly, expression of perilipin-2, an essential LD protein 
component, was higher in E4 astrocytes. We then probed fatty acid (FA) metabolism and 
found E4 astrocytes to exhibit decreased uptake of palmitate, and decreased oxidation of 
exogenously supplied oleate and palmitate. We then measured oxygen consumption rate, 
and found E4 astrocytes to consume more oxygen for endogenous FA oxidation and 
accumulate more LD-derived metabolites due to incomplete oxidation. Lastly, we found 
that E4 astrocytes are more sensitive to carnitine palmitoyltransferase-1 inhibition than E3 
astrocytes. These findings offer the potential for further studies investigating the link 





Apolipoprotein E (apoE) is associated with circulating lipoproteins, specifically very 
low-density lipoproteins and high-density lipoproteins (271). The polymorphic APOE gene 
encodes for three isoforms, E2, E3, and E4, with frequencies of 8%, 77%, and 15%, 
respectively, in the general US population (59). E4 is the strongest genetic risk factor for 
late onset Alzheimer’s disease (AD) (59). In addition to established effects on AD 
neuropathology, APOE genotype is also recognized as a strong modulator of cerebral 
metabolism (4, 68, 272, 273). In fact, cognitively normal E4+ individuals demonstrate 
alterations in cerebral fatty acid (FA) and carbohydrate metabolism congruent with AD 
patients (3, 4). Understanding the metabolic effects of apoE in the brain may be a critical 
step in discovering the underlying mechanism(s) of E4-driven AD risk.  
The brain is one of the largest site of apoE synthesis, second to the liver (274). The 
majority of brain apoE is astrocyte derived, though under certain conditions such as trauma, 
neurons and microglia also synthesize apoE (275). ApoE binds to receptors of the low-
density lipoprotein receptor family, which are expressed on astrocytes as well as neurons 
(276). Astrocytes aid in shuttling lipids from the blood-brain barrier (BBB) to neurons by 
both binding and internalizing BBB permeable FAs from the endothelial cells, and loading 
lipid-free apoE with cargo through action of the ATP-binding cassette transporters such as 
ABCA-1 (277, 278). Therefore, astrocytes are key players in the lipid uptake-apoE-
lipidation axis, and are vital to maintaining brain lipid homeostasis and proper neuronal 
function. Not only are astrocytes critical for uptake and export of FAs and lipid-loaded 
lipoproteins, they also are the main cell population mediating β-oxidation of FAs in the 
brain (279, 280). Astrocytes contain a higher relative density of mitochondria than the 
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surrounding neuropil, giving them superior machinery to oxidize FA (281). Furthermore, 
carnitine palmitoyltransferase-1 (CPT-1), an essential enzyme for the beta-oxidation of 
long chain FA, is preferentially expressed in astrocytes compared to neurons, microglia, 
and oligodendrocytes (282). Recent studies clearly show that the brain does in fact utilize 
a significant amount of FAs, with some reports estimating FAs are responsible for up to 
20% of cerebral ATP generation (280, 283). 
Lipid droplets (LD) are organelles containing triacylglycerols and cholesterol esters 
surrounded by a layer of amphipathic lipids and associated proteins. Once thought to be 
inert cellular depots of fat, lipid droplets are now considered to be dynamic organelles that 
play a role in various metabolic diseases (139, 284). Indeed, the overaccumulation of LDs 
has been linked to atherosclerosis, metabolic syndrome, cancer, and diabetes (285, 286). 
However, only recently have studies begun to address the potential pathological 
consequences of abnormal LD accumulation in the brain (284). Although low amounts of 
LD are observed in the brain under normal conditions (165), studies have noted increased 
LD content in neurodegenerative conditions such as Parkinson’s (208) and AD (181, 219). 
Interestingly, Alois Alzheimer noted glial lipid accumulation in his first description of AD 
pathology (218), but this has gone relatively unstudied apart from a few reports linking 
LDs and AD (128, 181). Recent findings suggest that glial cells within the brain form LD 
as a function of neuronal stress, and in the fly brain this process is apoE dependent (128). 
Astrocyte derived E4 has been shown to promote LD formation in fibroblasts (287), and 
iPSC-derived astrocytes expressing E4 exhibit increased lipid storage in the form of 
cholesterol (34). E4 astrocytes also show varied expression of numerous genes associated 
with lipid metabolism and transport, compared to those expressing E3 (34). However, 
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apoE-isoform specific modulation of LD accumulation and FA metabolism in astrocytes 
has not been previously described. 
In this study, we characterize an increase in lipid droplet formation and endogenous 
FA utilization in E4 astrocytes, as well as decreased uptake and oxidation of exogenous 
FAs. These lipid metabolism events influenced by APOE offer both targets for future late 
onset AD therapies and potential for more studies analyzing the metabolic effects of APOE 
in the brain.  
4.2 Methods 
4.2.1 Cell Culture  
E3 and E4 expressing astrocytes were derived from targeted replacement mice 
expressing human APOE3 or APOE4 (kind gift from Dr. David Holtzman). These cell lines 
secrete apoE in high density lipoprotein-like particles at equivalent levels to primary 
astrocytes from targeted replacement APOE knock-in mice and have been relied upon for 
studies of APOE’s role in astrocyte metabolism by many groups (91-93, 97). Cells were 
maintained in Advanced Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Carlsbad, 
CA, USA) supplemented with 1 mM sodium pyruvate, 1× Geneticin, and 10% fetal bovine 
serum. For imaging experiments, cells were grown on sterilized coverslips in 6-well plates 
pre-treated with poly-L. For lipid loading experiments, 250 µM oleate pre-conjugated to 
bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA) was added to the media 24 h 
prior for lipid droplet induction as previously described (288).  
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4.2.2 Western Blotting 
Cells were lysed on ice using radioimmunoprecipitation assay Buffer (Thermo 
Fisher Scientific, Waltham, MA, USA) with 1× proteinase inhibitor (Sigma, St. Louis, MO, 
USA ). Protein concentration was determined by Pierce bicinchoninic acid (BCA) protein 
assay (Thermo Fisher Scientific, Waltham, MA, USA). 20–30 µg of protein was diluted 
with 2× Laemmli Sample Buffer (Bio-Rad Laboratories, Hercules, CA, USA) and heated 
at 100 °C for 10 min. Protein samples were then loaded on 4–20% PROTEAN TGX gels 
(Bio-Rad Laboratories, Hercules, CA, USA) for SDS-PAGE. Gels were transferred using 
a Trans-Blot Turbo Transfer system (Bio-Rad Laboratories, Hercules, CA, USA ) onto 
polyvinylidene fluoride  membrane. Membranes were then blocked for 2 h in 1% casein 
and then incubated overnight in primary antibody solution (1:1000 PLIN-2 (Novus 
Biologicals, Centennial, CO, USA); 1:1000 APOE (Abcam Inc., Cambridge, MA, USA); 
1:1000 β-actin (Novus)) at 4 °C. Membranes were then washed three times for five minutes 
each with PBS, pH 7.4, 0.05% Tween-20, and then incubated with secondary antibody 
solution (1:10,000 Goat α rabbit IR 680 (LI-COR, Lincoln, NE, USA); 1:5000 goat α 
mouse IR 800 (LI-COR)) for 2 h at room temperature. Membranes were then washed as 
before, with an additional two 10 min washes in PBS. Images were acquired on a LI-COR 
Odyssey Infrared Scanner. Resulting images were exported to ImageJ for blot densitometry 
and quantification.  
4.2.3 Lipid Droplet Imaging 
After lipid incubation, coverslips were lifted from the wells and cells were fixed for 
15 min in 4% PFA, washed 1× with PBS, and incubated for 30 min in 1:1000 LipidSpot 
76 
 
(Biotium, Fremont, CA, USA). Coverslips were then mounted onto slides using 
Fluoroshield mounting media with DAPI (Abcam). Slides were kept at 4 °C. Wide field 
images were obtained on a Nikon Ti2 microscope using a 20× objective. Single cell images 
were obtained on a Nikon A1R Laser Scanning Confocal Microscope (Nikon, Tokyo, 
Japan) using an oil immersed 100× objective. Astrocytes were selected in the 405 channel 
(DAPI-stained nuclei) and then the 610 channel was added (LipidSpot-stained LDs) and 
the images were captured. Z-stacks were taken in a range of 10 µM, 40 images per stack. 
3-D reconstructions were processed in Imaris 9.2 software using the surfaces module to 
obtain statistics for lipid droplets. Experimenter was blind to slide identity and slides were 
processed in random order under identical microscope settings.  
4.2.4 Fatty Acid Uptake Assay 
Astrocytes were plated at 50,000 cells/well in CytoStar T plates (Perkin Elmer, 
Waltham, MA, USA) and allowed to grow to confluency. Media was aspirated, and new 
glucose free media supplemented with either 0.5 µCi/mL 14C-palmitate or 14C-oleate 
(Perkin Elmer) was added to the wells. Scintillation bead technology in the wells emitted 
light proportionate to the cellular uptake of the FA (289). Radioactivity counts were read 
on a Microbeta 2 Microplate Counter (Perkin Elmer) and normalized to protein content in 
the well using a BCA assay (Thermo Fisher Scientific, Waltham, MA, USA).  
4.2.5 Fatty Acid Oxidation Assay  
Astrocytes were plated in a 24-well plate at 300,000 cells/well and allowed to grow 
to confluency for 24 h. Using a previously published protocol (290), cells were then 
incubated with 0.5 µCi/mL [1-14C] palmitate or 0.5 µCi/mL [1-14C] oleate for 24 or 3 h. 
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For the pulse experiment (exogenously supplied FA) radiolabeled FAs were added in 
nutrient depleted media (Glucose Free DMEM; 5% FBS) for 3 h. Buffered 14CO2 in the 
media was then liberated by addition of 1 M hydrochloric acid and captured on a filter 
paper disc pre-soaked with 1N sodium hydroxide. For the pulse chase experiment 
(endogenous FA), radiolabeled FAs were added in nutrient rich media (25 mM Glucose; 
10% FBS) for 24 h, then aspirated and nutrient depleted media was added to promote 
oxidation of fatty acid from intracellular lipid pools. Radioactivity of the filter paper was 
measured in a Microbeta 2 Microplate Counter after addition of 3 mL Ultima-Gold 
Scintillation Fluid. Acid soluble metabolites, which represent incomplete oxidation of the 
fatty acids, were extracted from the media and cellular fractions. Total protein from each 
well was assayed using a BCA assay (Thermo) and all radioactivity measures were 
normalized to protein content.  
4.2.6 Seahorse Extracellular Flux Analysis 
Astrocytes expressing E3 or E4 were seeded in a 96-well microplate at 50,000 
cells/well and left to form a monolayer overnight. Media was aspirated and 135 µL of 
limited nutrient running media (DMEM; 5 mM glucose, 2.5 mM carnitine, 5 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) was added to each well and allowed to 
incubate for 1 h. Then 30 µL of 1 mM sodium palmitate complexed to BSA (6:1 molar 
ratio) or BSA alone was added to wells according to group assignment, at which point the 
oxygen consumption rate (OCR) was determined by a Seahorse Extracelluar Flux Analyzer 
xF96 (Agilent, Santa Clara, CA). At each successive 18 min, an injection of 200 µM 
etomoxir, 1 µM oligomycin, or 1 µM Rotenone | Antimycin was added to each well to 
inhibit carnitine palmitoyltransferase-1 (CPT-1), ATP synthetase, or complex I and III 
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respectively. OCR was measured every 6 min. Values were normalized to protein content 
in each well by a BCA Assay (Thermo). OCR from endogenous FA oxidation was 
determined by calculating the average etomoxir effect in BSA treated astrocytes (Equation 
(1)).  
𝑂𝐶𝑅̅̅ ̅̅ ̅̅ 𝐸𝑛𝑑𝑜 𝐹𝐴𝑂 = 𝑂𝐶𝑅̅̅ ̅̅ ̅̅ 𝑃𝑟𝑒−𝐸𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂𝐶𝑅̅̅ ̅̅ ̅̅ 𝑃𝑜𝑠𝑡−𝐸𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙  (1) 
OCR from exogenous FA oxidation was determined by calculating the average difference 
in basal OCR in the palmitate treated astrocytes versus the basal OCR in BSA treated 
astrocytes (Equation (2)).  
𝑂𝐶𝑅̅̅ ̅̅ ̅̅ 𝐸𝑥𝑜 𝐹𝐴𝑂 = 𝑂𝐶𝑅̅̅ ̅̅ ̅̅ 𝑃𝑟𝑒−𝐸𝑡𝑜 𝑃𝐴 − 𝑂𝐶𝑅̅̅ ̅̅ ̅̅ 𝑃𝑟𝑒−𝐸𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙  (2) 
4.2.7 Statistical Analysis 
All data are expressed as mean  ±  standard error. Comparisons between two groups 
were analyzed by t-test. Multiple groups and/or multiple time points were analyzed using 
ANOVAs (Prism, Graphpad, San Diego, CA, USA), or repeated measures ANOVA (time  
×  groups) (SPSS). Statistical significance was determined using an error probability level 






4.3.1 E4 Astrocytes Display Increased LD Count, Increased Cellular LD Volume, 
Decreased LD Size  
We first asked if APOE influences lipid storage within astrocytes. To answer this, 
we lipid-loaded E3 and E4 astrocytes with 250 μM oleate for 24 h, stained for neutral LDs 
(Figures 1A and S3A), and quantified LDs per cell (Figures 1B and S3B). E4 astrocytes 
showed a significant increase in the number of LDs, both at basal levels and in a FA-rich 
environment, compared to E3. (Figure 4.1B) Total LD volumes within the cell were also 
analyzed, and E4 astrocytes held significantly more lipid volume under lipid loaded 
conditions compared to E3. (Figure 4.1C). Furthermore, expression of perilipin-2 (PLIN-
2), a LD associated protein, was increased in E4 astrocytes in an FA-rich environment 
compared to E3. (Figure 4.1D–E; Appendix 2.1).  
To determine LD size and distribution, LDs in individual cells were rendered using 
Imaris software under control and lipid-loaded conditions (Figure 4.2A), and volumes were 
quantified (Figure 4.2B–D) and binned using 0.1 µm as a bin size. It was found that E4 
astrocyte LDs were on average 54.8% smaller on a volume per droplet basis than E3s under 
control conditions, and 33.7% smaller when lipid-loaded. Together, these results suggest 
that E4 astrocytes form more LDs than E3 astrocytes regardless of FA exposure, as 
reflected in increased expression of PLIN-2 and an increased LD count.  




Hypothesizing that an increase in lipid storage may be a result of increased uptake 
of FAs, we next sought to determine if APOE regulates astrocyte FA uptake. Using a 
scintillation proximity assay and treating with 14C-labeled FAs, we found E4 astrocytes to 
take up significantly less palmitate (Figure 4.3A–B), with no significant difference in 
oleate uptake (Figure 4.3C). Conversely, there was a trend toward increased oleate uptake 
in E4 astrocytes, with cumulative uptake slightly higher when expressed as the area under 
curve despite lacking statistical significance. (Figure 4.3D) These data suggest that APOE 
isoforms may modulate FA uptake in astrocytes dependent on the FA species.  
4.3.3 E4 Astrocytes Oxidize Less Exogenous Fatty Acids 
We next examined how APOE might regulate FA oxidation in astrocytes. We first 
assessed how E3 and E4 astrocytes oxidize exogenously supplied FA. We treated cells with 
radiolabeled palmitate or oleate for 3 h in a nutrient depleted media, and captured the 
oxidation product CO2, as well as incompletely oxidized products of FA metabolism in the 
form of acid soluble metabolites (ASM). (Figure 4.4A). We found that E4 astrocytes 
oxidize significantly less exogenously supplied oleate and palmitate than E3 astrocytes 
(Figure 4.4B), and instead accumulate significantly more metabolites that are acid soluble 
(Figure 4.4C–D); these ASM include ketone bodies, acyl carnitines, citric acid cycle  
intermediates, and FA less than six carbons in length (290). We found an increased 
concentration of these ASM inside E4 cells (Figure 4.4C). We also found an increased 
concentration of ASM in the media (Figure 4.4D), suggesting that E4 astrocytes may export 
more FA metabolites than E3s. Using Seahorse Extracellular Flux Analysis, we then 
measured the oxygen consumption rate (OCR) before and after inhibition of CPT-1 in E3 
and E4 astrocytes supplied with palmitate in the media (Figure 4.4E). We found E4 
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astrocytes to exhibit a lower OCR compared to E3 at all time points (Figure 4.4E). This 
lower OCR is likely primarily due to a decreased rate of glucose oxidation, as E4 is strongly 
associated with a phenotype of glucose hypometabolism (4, 48). When we specifically 
calculated the contribution of FA oxidation to OCR by comparing basal OCR in palmitate 
treated versus BSA treated astrocytes, we found that E4 astrocytes utilize significantly less 
exogenously supplied FA as part of their basal respiration. (Figure 4.4F) 
Since E4 astrocytes showed a significant increase in LD accumulation, we next 
studied how APOE modulates FA oxidation from intracellular FA pools. Knowing that 
incubation with oleate for 24 h induces LD formation, we “pulsed” E3 and E4 astrocytes 
with radiolabeled FAs for 24 h to incorporate the radiolabel into LDs (Figure 4.5A). We 
then aspirated the media, washed with PBS, and captured oxidation and non-oxidation 
products of the intracellular FAs after a 4 h “chase”. Interestingly, in contrast to the 
oxidation of exogenously supplied FA, E3 and E4 astrocytes showed no difference in CO2 
production from intracellular pools of oleate or palmitate (Figure 4.5B). Quantification of 
ASMs of intracellular palmitate and oleate revealed that E4 astrocytes once again exported 
significantly more ASM into the media (Figure 4.5C), and have similar levels within the 
cells (Figure 5D). We next quantified OCR using Seahorse in E3 and E4 astrocytes that 
were incubated in serum free media and not supplied with exogenous FA (Figure 4.5E), 
assuming the only source of FA would be from intracellular LDs. We found that the OCR 
in E4 astrocytes that could be attributed to oxidation of endogenous FA was significantly 
higher than E3 astrocytes, suggesting that while CO2 production is similar between 
genotypes, E4 astrocytes seem to consume more oxygen from the metabolism of 
intracellular FAs (Figure 4.5F). Together these data suggest that APOE alters FA oxidation 
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in astrocytes, and that these effects differ depending on the source of FAs (endogenously 
stored as LD vs exogenously supplied in media) 
 
4.3.4 E4 Astrocytes Are More Sensitive to CPT-1 Inhibition 
Since CPT-1 is the rate-limiting enzyme of fatty acid oxidation, we hypothesized 
that E3 and E4 astrocytes may exhibit varying responsiveness to CPT-1 inhibition. Using 
Seahorse, we measured OCR before and after CPT-1 inhibition with etomoxir and assessed 
the percent change in OCR from baseline in E3 and E4 astrocytes pretreated with palmitate 
and the non-pretreated control cells (Figure 4.6A). We found that E4 astrocytes have a 
significantly larger drop in OCR after CPT-1 inhibition compared to E3 astrocytes in both 
pretreated and control cells, suggesting an increased reliance on FA oxidation for overall 
OCR (Figure 4.6A).  
To determine if CPT-1 inhibition results in APOE genotype specific effects on 
palmitate and oleate oxidation, we used a 14CO2 trap approach and found E4 astrocytes to 
exhibit a greater fold change in oxidation of palmitate from the baseline after CPT-1 
inhibition (Figure 4.6B). However, we saw no differences between genotypes with regards 
to the etomoxir effect on oleate oxidation (Figure 4.6B), again suggesting these APOE 
effects may be specific to certain FA species. 
4.4 Discussion 
Lipid droplets in astrocytes serve to both sequester fatty acids that would otherwise 
be cytotoxic if free in the cytoplasm and to offer an energy rich and accessible pool for 
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cellular metabolic needs in times of starvation and stress. Recent studies of AD brain tissue 
have demonstrated an increase in LDs (181, 219). ApoE is an important component of 
peripheral and central nervous system lipoproteins, which share many biochemical features 
with LDs (139). The E4 allele of APOE is a critical genetic risk factor for late onset AD, 
and is strongly associated with a number of metabolic abnormalities (4, 34, 42, 47). 
However, the link between E4 and LD biology has not been widely explored. In the current 
study, we characterized a number of apoE isoform specific differences in LD formation 
and FA utilization in astrocytes. 
We found that E4 astrocytes form many small LDs compared to the few large LDs 
observed in E3 astrocytes. The structural makeup of LDs could be a contributor to overall 
LD size. Surfactant lipids such as phosphotidylcholine (PC) are known to stabilize LD 
emulsions, while more fusogenic lipids, such as phosphatidic acid, promote LD 
coalescence (139, 291). Our group previously showed that E4 mice brains differ in various 
lipid concentrations using an unbiased metabolomics approach(51). Interestingly, 
Heinsinger et al. recently showed that the apoE isoforms are associated with varying sizes 
of CNS lipoproteins, with E4 individuals and astrocytes synthesizing smaller apoE-
associated lipoprotein particles (292). As the structure and makeup of LDs and lipoproteins 
are similar, it is possible that E4 promotes smaller spherical lipid carriers whether that be 
inside or outside the cell. Overall isoform specific effects on FA metabolism could also be 
a result of differing total concentrations of apoE. E4 astrocytes are known to secrete less 
apoE into the media and have less intracellular apoE (Figure S2) (97), and E4 brains from 
targeted replacement mice have less apoE (293). Whether the lower quantity of apoE4 in 
E4 carriers is related to disease pathogenesis is unknown.  
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LD associated proteins, such as perilipins, serve to stabilize the LD from excessive 
lipolysis. Loss of perilipin-2 has been associated with an increase in endogenous fatty acid 
oxidation (294). We found that E4 astrocytes exhibit increased expression of perilipin-2, 
decreased exogenous FA oxidation, and increased oxygen consumption from endogenous 
fatty acid oxidation. Overexpression of PLIN2 has been liked to a decrease in glucose 
uptake by LD sequestration of key regulators of glucose transporters (295). In unpublished 
work, our group found that E4 down-regulates astrocyte glucose metabolism, much like 
the effects reported in neuronal models of apoE overexpression (47). It may be that the 
energetic needs of an E4 astrocyte in the absence of robust glucose metabolism overpower 
the inhibitory effect of PLIN2 on LD lipolysis. The overexpression of PLIN2 has also been 
shown to increase LD formation in various cell types (190, 296, 297). This is congruent 
with our findings in regards to E4 astrocytes, where an increase in LD number paralleled 
with increased PLIN2 expression. In hepatocytes, increased levels of reactive oxygen 
species (ROS) prompt increased PLIN2 expression subsequent LD formation (190). ROS 
has been linked to LDs in glia in a Drosophila model as well, and this process was found 
to be apoE dependent (128, 192). Oxidative stress as an inducer of LDs in astrocytes as a 
function of APOE deserves further investigation in light of the poor anti-oxidant capacity 
of E4 (298). Alternatively, the presence of many small droplets as opposed to larger 
droplets could be a result of increased FA oxidation resulting from LD turnover. More 
studies are needed in CNS in vitro models to define LD metabolism and how it may differ 
from peripheral LD metabolism.  
E4 carriage in humans seems to promote an “accelerated AD” status, particularly in 
terms of cerebral glucose metabolism (4). Namely, as individuals transition through mild 
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cognitive impairment to AD, glucose metabolism progressively decreases in several 
distinct brain regions (299, 300). E4 individuals, however, show a state of glucose 
hypometabolism in these same regions even in the absence of cognitive impairment, and 
as early as the third decade of life (3). LDs are known to increase in cerebral density with 
age and are found in GFAP+ cells (175). E4 carriers show an accelerated development of 
AD neuropathology and cognitive symptoms, and astrocytes have been shown to play a 
key role in E4-driven AD pathogenesis (301). Perhaps this accelerated AD phenotype in 
E4 individuals extends to cerebral LD accumulation as well.  
It has been proposed that E4 carriers may be at risk for cognitive decline because of 
an E4-driven disruption in FA metabolism (302, 303). Here we showed that APOE 
regulates fatty acid metabolism in the astrocyte depending on the saturation status of the 
fatty acid. We observed marked decrease in uptake of the fully saturated fatty acid 
palmitate in E4 astrocytes compared to E3 astrocytes while no difference was observed in 
oleate uptake. When we treated with etomoxir, we saw drastic reduction in oleate oxidation 
in both genotypes, but much less of a reduction in oxidation in E3 astrocyte palmitate 
oxidation compared to E4. These data may shed light on a phenomenon seen in 
epidemiological studies where E4 carriers respond well to an acute high fat meal (by 
cognitive measures and plasma AD biomarkers), while non-E4 carriers responded poorly 
(10). This may be due to a lower uptake of saturated fatty acids. Conversely, E4 carriers 
have been shown to exhibit increased uptake of unsaturated fatty acids, specifically 
docosahexaenoic acid (304). This could be related to the preventative effect of a Nordic 
diet rich in fish, fruits, and vegetables on cognitive decline in E4 individuals (23). Indeed, 
apoE isoform specific effects on lipid usage have been characterized systemically, wherein 
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E4 mice show a metabolic preference for oxidizing FAs (111). Related FA disturbances 
have been characterized in humans carrying E4. For instance, E4 carriers show greater 
uptake, brain incorporation, and whole-body β-oxidation of docosahexaenoic acid 
compared to non-E4 carriers (28, 304). In the current study, our data using 14C-labeled FAs 
support the idea that E4 alters the flux of metabolites into the TCA cycle and because of 
this, decreases CO2 production and increases metabolites that are acid soluble. Our group 
previously showed that E4 alters numerous pathways within the cerebral metabolome (51), 
and others have shown changes in TCA specific metabolites in the brain (305).  
4.5 Conclusion 
In this study we showed that E4 astrocytes display an increase in LD formation 
compared to E3 astrocytes. Specifically, E4 astrocytes have a higher number of smaller LD 
and increased expression of the LD marker PLIN2. We also observed increased oxygen 
consumption rates from endogenous fatty acid oxidation, decreased rates of exogenous 
fatty acid oxidation, and an increased sensitivity to CPT-1 inhibition in E4, compared to 
E3, astrocytes. While a number of important questions remain, we hope these initial 
findings will serve as a basis for the further study of APOE-associated alterations in 







Figure 4.1 E4 astrocytes have increased lipid droplet (LD) count, LD volume, and LD 
associated protein. 
(A) Astrocytes expressing either E3 or E4 were stained with LipidSpot to quantify lipid 
content under control conditions (left), and after 24 h oleic acid (OA) supplementation 
(“lipid-loaded”; right). The number of LDs per individual cell (B) and total LD volume per 
cell (C) were quantified. Values represented are means +/− SEM (n = 10). Data were 
analyzed by t-test for specific comparisons between means; * p <0.05. (D) Representiative 
image of the total expression of perilipin-2 (PLIN2) and β-actin in control or lipid-loaded 
E3 and E4 astrocytes was determined by SDS-PAGE and Western blotting and quantified 
(E). Values represent mean +/− SEM (n = 3). Data were analyzed by by t-test; * p <0.05. 





Figure 4.2 E4 astrocytes have smaller lipid droplets. 
(A) Representative 3D renderings of E3 and E4 astrocytes stained with LipidSpot and 
DAPI under control and lipid-loaded conditions. (B) Individual lipid droplet (LD) volume 
was quantified under control and lipid-loaded conditions. Values represented are means 
+/− SEM. Data were analyzed by unpaired t-test; *** p <0.001, * p <0.05. (C) Relative 
frequencies of LD volumes were binned between 0 and 1 µm3 under control and (D) lipid 
loaded conditions. Bin size = 0.1 µm3. E3 control LDs (n = 131); E4 control LDs (n = 775); 





Figure 4.3 E4 astrocytes uptake less palmitate, but not oleate. 
E3 and E4 astrocytes were treated with 0.5 µCi/mL [1-14C] palmitate (A,B) or (C) [1-14C] 
oleate (C,D) and uptake was measured over 150 min by a scintillation proximity assay. 
Values represent mean +/− SEM (n = 6). Data were analyzed by two-way ANOVA of 
repeated measures (A,C) or t-test (B,D); * p <0.05. Total area under the curve (AUC) was 







Figure 4.4 E4 astrocytes oxidize less exogenously supplied fatty acids. 
(A) Schematic and summary of pulse experiment to determine oxidation of exogenously 
supplied fatty acids. (B) E3 and E4 astrocytes were treated with [1-14C] oleate (OA) or [1-
14C] palmitate (PA) and oxidation was measured over 3 h by a CO2 trap assay. Acid soluble 
metabolites were quantified in media (C) and intracellular (D) fractions. Values represent 
mean +/− SEM (n = 6). Data were analyzed by t-test;*** p < 0.001, **** p < 0.0001. (E) 
E3 and E4 astrocytes were pretreated for 1 h with palmitate and subjected to a Seahorse 
Extracellular Flux Fatty Acid Oxidation Assay. Vertical gray dashes indicate time points 
of pharmacological injections of etomoxir (Eto), oligomycin (Oligo), or Rotenone and 
Antimycin (RA). (F) Oxygen consumption due to FA oxidation of exogenously supplied 
palmitate was determined (see methods) and graphed. Values represent means +/− SEM (n 




Figure 4.5 E4 astrocytes oxidize more endogenous fatty acids. 
(A) Schematic and time-course of pulse-chase experiment to determine oxidation of 
endogenous fatty acids.. (B) E3 and E4 astrocytes were treated with 1 µCi/mL [1-14C] 
oleate (OA) or [1-14C] palmitate (PA) combined with non-labelled isotopes to 200 µM in 
Advanced DMEM for 24 h, washed with PBS, and then oxidation was measured over 4 h 
in a nutrient depleted media by a CO2 trap assay. Acid soluble metabolites were quantified 
in media (C) and intracellular (D) fractions. Values represent mean +/− SEM (n = 6). Data 
were analyzed by t-test; ** p < 0.01, *** p < 0.001; **** p < 0.0001. (E) E3 and E4 
astrocytes were pretreated for 1 h with bovine serum albumin supplemented media and 
subjected to a Seahorse Extracellular Flux Fatty Acid Oxidation Assay. Vertical gray 
dashes indicate time points of pharmacological injections of etomoxir (Eto), oligomycin 
(Oligo), or Rotenone and Antimycin (RA). (F) Oxygen consumption due to intracellular 
FA oxidation was determined (see methods) Results were normalized to protein content. 





Figure 4.6 E4 astrocytes are more sensitive to CPT-1 inhibition. 
(A) Percent change in OCR for E3 and E4 astrocytes pretreated with BSA or palmitate-
BSA. Data represent mean of replicate wells +/− SEM (n = 3–4). Data were analyzed by 
two-way ANOVA, repeated measures; **** p <0.0001. (B) Fold change in oxidation of 
oleate (OA) or (PA) due to carnitine palmitoyltransferase 1 (CPT-1) inhibition was 
determined by CO2 trap assays and represented as mean of replicate wells +/− SEM (OA: 








CHAPTER 5. DISCUSSION AND EXPERT OPINION 
5.1 Summary of dissertation 
 This dissertation work leverages human data, humanized mice models, and cutting 
edge in vitro assays of metabolism to detail a role for the gene APOE as a metabolic 
regulator at the cellular and organismal level. APOE has been studied extensively in the 
context of neurodegeneration and neuropathology, peripheral lipid transport, and 
cardiovascular disease (306). Here, APOE genotype is revealed to glucose flux through 
central carbon pathways in astrocytes, manifesting at the systemic level by decreasing 
energy expenditure in E4 carriers – a phenomenon which can be measured via indirect 
calorimetry. Furthermore, a role for APOE in lipid droplet formation and utilization is 
detailed in astrocytes. The literature and field of APOE metabolism regulation in the brain 
and beyond is growing, and this body of work contributes substantially to our budding 
understanding of this crucial gene. 
5.2 APOE in human health 
The polymorphic APOE gene encodes for three alleles in humans:  E2, E3, and E4 
(307). E3 has the highest allelic representation in the human population with 78% of 
individuals carrying at least one copy of E3. E2 represents the smallest percentage of the 
population at 8%. E4 carriers constitute 14% of the global population (1). Though APOE 
alleles differ by single polymorphisms at two genetic loci, the alleles confer a range of 
pleiotropic phenotypes. E4 is the strongest genetic risk factor for the development of late 
onset Alzheimer’s disease, while E2 offers protection and is associated with longevity (59). 
The E2 allele differs from the E4 allele by two amino acids (at AA 112 and AA 158) yet 
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according to recent estimates lowers the odds ratio of developing late onset Alzheimer’s 
disease by nearly hundredfold (308). A step wise progression of increased risk to decreased 
risk with allelic dose (E4>E3>=E2) is seen in multiple diseases of the central nervous 
system including dementia with Lewy bodies, frontotemporal lobar degeneration, 
Parkinson’s disease, ischemic stroke, and vascular dementia (58). Furthermore, E4 
increases the risk of diseases commonly thought of as diseases of the periphery, such as 
hypercholesterolemia, coronary artery disease, atherosclerosis, and metabolic syndrome 
(307, 309). The range of diseases, central and peripheral, associated with APOE suggests 
that APOE plays a multifaceted role in human health.  
5.3 Antagonistic pleiotropy as an explanation for APOE4 population frequency  
 A common question regarding the genetic frequency of APOE4 is:  if E4 drives so 
much disease risk, how could it still be selected for evolutionarily in our population? This 
is likely answered by the increase in human life expectancy across history (310). We now 
live longer than ever before as humans, which may be revealing age-dependent genetic 
effects which may have conferred advantages in our youth (and in ancestors with shorter 
lifespans) but be pathogenic in old age. This concept is known as antagonist pleiotropy and 
is supported by advantageous characteristics of young E4 carriers which are lost with age 
(311, 312).   
5.3.1 APOE4 as the ancestral allele 
 To consider APOE and its relevance to human health it is useful to phylogenetically 
trace the gene’s evolution, which is now feasible based on advances in molecular genetics 
and anthropology. APOE is genetically conserved across mammalian and non-mammalian 
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species, reflecting an ancient entry of APOE as a component of organismal genomes (313). 
Mice possess an Apoe gene with a similar amino acids at AA 112 and AA 158 as human 
APOE4, yet the protein behaves functionally similar to human ApoE3 since it does not bear 
the domain-interaction observed in the protein structure of ApoE4 (314). Interestingly, this 
shared sequence of APOE4 between humans and lower vertebrates, including non-human 
primates, gives support for the theory that APOE4 is the ancestral allele, and that the other 
alleles arose from evolutionary selection (315). This is also supported by the geographical 
distribution of the alleles across the continents; APOE4 has a much higher population 
frequency in the indigenous populations of Central Africa (40% in Aka Pygmies, 38% in 
Tutsis, 33% in Zairians, and 29% in Fon), Oceania (49% in the Hui population of New 
Guinea), and Australia (26% in the Mowanjum aboriginal tribe) relative to its worldwide 
frequency (316, 317). Therefore it appears that APOE4 was the original allele in our ancient 
ancestors. 
5.3.2 Unique human APOE polymorphisms 
 The polymorphic nature of APOE in humans is unique (318). No other species 
known to date has multiple common alleles for the APOE gene. Therefore, if we assume 
that APOE4 was the ancestral allele and evolutionary pressures gave rise to APOE3 and 
APOE2, it would seem that these evolutionary pressures were unique upon the human 
species. If a global event had occurred that would have selected for mutations in the APOE4 
common ancestral allele, more species would likely share the polymorphic APOE as seen 
in humans.  
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5.3.3 Historical shift in human feeding patterns 
 In the course of human history it has been necessary to metabolically adapt to our 
environmental energy supply apart from other species. Ancient humans likely were 
stationary until resources were depleted relative to the population size, which then required 
humans to compete for resources (319). With territorial disputes and large-migrations away 
from resources, human metabolism was challenged to adapt due to food scarcity. Pre-
historic hunter gatherers were accustomed to a “feast and then fast” dietary program and 
required metabolic adaptations to fuel the body in times of starvation to adequately store 
energy during times of energy availability to permit survival. Extended foraging distances 
required endurance and conversion of bodily energy stores into usable energy substrates 
critical to maintain energy homeostasis (320). As the body begins a period of fasting, 
energy stores are tapped, releasing non-esterified fatty acids from lipolysis of triglyceride 
adipose reservoirs, glucose from glycogen stores and gluconeogenesis, and amino peptides 
from proteolysis. Importantly, genes that promoted energy pool tapping and utilization 
would have been selected for in the gene pool during this period of human evolution. 
Conversely, genes that are associated with impairments or inefficiencies in energy 
utilization would likely be negatively selected. This may help explain why APOE, a gene 
associated with mobilization of fatty acids for energy, is polymorphic in humans alone. It 
may be that E3 and E2 conferred metabolic advantages over the E4 allele in our human 
ancestors that resulted in the current population frequencies millennia later. It is also 
possible that E4 was the advantageous allele for the hunter gatherer population due to its 
“thrifty” nature allowing extended lipoprotein circulation and increased storage (317).  
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5.3.4 Modern day feeding on the background of inherited ancestral genetics 
Shifting to the present, we are now accustomed to an excess of caloric availability 
and modern humans typically follow a “feast and then feast” diet. Therefore, processes of 
energy management and efficiency are relatively less active in modern humans consuming 
excess calories compared to our ancestors. The increase in caloric consumption and our 
increased life expectancy has occurred relatively rapidly. Yet, our species carries the 
genetic profile of humans in a world where energy was scarce, feeding was rare, and life 
expectancy was shorter.  
 This drastic shift in our energy availability and consumption has occurred in 
parallel with a rise in the incidence of diseases of metabolic dysfunction including type 2 
diabetes, metabolic syndrome, and obesity. These diseases of metabolic dysfunction 
increase the risk of dementia and share several pathological characteristics with 
Alzheimer’s disease (AD), such as inflammation, increases in oxidative stress and vascular 
dysfunction (321, 322). Metabolic disorders also increase in incidence with age, (323) and 
a rapidly aging demographic means the number of individuals suffering from both 
metabolic disorders and AD is expanding precipitously. While diet has been proven to play 
a role in the rise of these diseases, the influence of diet-by-gene interactions on disease risk 
is just beginning to be understood.  
5.4 APOE, astrocytes, and cerebral metabolic flexibility 
Normal brain function requires a multitude of energy-intensive processes, and a 
complex and intricately linked interplay between neurons and supporting glia is necessary 
to maintain efficient energy metabolism. Astrocytes in particular play a critical role in brain 
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homeostasis, regulating both local energy metabolism and defense against oxidative stress, 
two aspects of great importance to neuronal viability and function (96, 324). Being the 
specialized metabolic neighbors of neurons, astrocytes bridge the distance between the 
vasculature and the energetically needy synaptic parenchyma. In contrast to neurons, 
astrocytes are highly glycolytic but also able to β-oxidize fatty acids (325, 326). This 
unique ability of fuel switching from primarily carbohydrate metabolism to fatty acid 
oxidation is vital for neuronal health in times of variable energy supply as in our ancestors’ 
environments. Metabolic inflexibility, that is the inability to utilize other substrates in the 
context of substrate deprivation, occurs in situations of caloric oversupply as a result of 
mitochondrial indecision (327). Essentially a traffic jam occurs at the key nodes of central 
carbon metabolism leading to metabolic gridlock instead of normal flux and energy 
production. This is detrimental in the brain where tight metabolic coupling between 
astrocytes and neurons depends on cooperative and smooth metabolic networks to sustain 
cerebral viability. Since astrocytes are the primary cell type in the brain to produce ApoE, 
and are key suppliers of metabolites to neurons, we chose to utilize in vitro astrocyte 
models to study the APOE genotype-specific alterations in fatty acid and glucose 
metabolism.  
5.4.1 Glucose hypometabolism as a shared feature of AD and E4 brains 
E4 carriers and individuals with AD both display an underutilization of glucose as 
a brain fuel source, seen early in AD disease progression and even in young and healthy 
E4 carriers (4). Even non-demented, cognitively normal E4 carriers demonstrate this 
pattern of glucose hypometabolism, thereby lending support to this being an inherent 
biological feature of E4, rather than simply a byproduct of dementia (3). Importantly, 
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glucose hypometabolism is considered the earliest detectable change in the AD brain 
regardless of APOE genotype, reflecting a pre-symptomatic biomarker and potential nidus 
for incipient AD (328). 
5.5 Metabolic inflexibility as a unifying mechanism to explain E4-associated 
antagonistic pleiotropy and disease risk  
It is possible that E4 drives glucose hypometabolism due to the metabolic gridlock 
associated with over consumption of energy substrates that is common in our modern era. 
While E4 conferred a survival advantage in hunter gathers when resources were scarce and 
energy storage was more important than energy utilization, today E4’s advantage is 
overcome by the carbohydrate rich diets of Western civilization which give E4 carriers an 
energy surplus that they are not adapted for. This metabolic indecision would occur at the 
level of the mitochondria, leading to overall decreases in ATP production, fuel oxidation, 
and glucose uptake due to negative feedback mechanisms.  
E4 as a driver of metabolic inflexibility would explain why in chapter 2 we 
observed increased lactate production in human, mice, and astrocytes fed glucose since the 
glucose is fluxed through aerobic glycolysis rather than the high energy yielding oxidative 
phosphorylation. We observed that deficits in oxidation and energy expenditure at baseline 
were exacerbated after a glucose challenge, implying that energy substrate supply (at least 
in terms of carbohydrates) worsens the E4 effect on metabolism. Previous work by our 
group demonstrated that mice fed a high fat diet also show exacerbated glucose metabolic 
impairments and worsened outcomes of cognition (43).  Lactate has been shown to 
compete with glucose for uptake and oxidation, as shown in chapter 2. Therefore, 
metabolic inflexibility is doubly problematic since energy oversupply leads to suppressed 
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glucose oxidation resulting in increased lactate which then also acts to impair glucose 
oxidation.  
Mitochondrial inflexibility would also explain why when we inhibited glutamine 
metabolism and fatty acid oxidation in E4 astrocytes, they were significantly less flexible 
at upregulating glucose oxidation relative to E3 astrocytes. It is important to note, however, 
that the energy substrates (glucose, fatty acids, glutamine) were all present during this 
experiment, and only pharmacological inhibitors were used to shut down metabolic 
pathways. This is distinct from a true “starvation” environment in which energy substrates 
would be absent.  
Regarding chapter 4, the E4 astrocytes were shown to increase storage of LDs and 
increase oxidation of the LD pools, but only when they were starved of glucose. That is, 
only when we removed the nutrient-dense media did we observe an increase in fatty acid 
oxidation from the LD pool over in E4 astrocytes relative to E3 astrocytes. This is 
consistent with the ‘thrifty’ gene hypothesis since E4 astrocytes showed an advantage in 
times of nutrient scarcity, and were shown to increase storage of energy substrates in times 
of nutrient abundance.  
Regarding chapter 1, many dietary interventions have been tried in E4 carriers with 
minimal success. Perhaps the repeated failures of dietary interventions can be explained by 
the nature of the dietary interventions, that is, the E4 carriers were still consuming an 
abundance of calories regardless of the type of diet. Dieting may not be the answer to 
mitigating E4 risk. Instead, I would advocate for a feeding regimen similar to our human 
ancestors. A diet with restricted feeding and intermittent fasting. To date, there has been 
no evidence based clinical study showing a beneficial (or non-beneficial) effect of 
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intermittent fasting in E4 carriers. However, a recent case report of a ketogenic diet 
intervention in a morbidly obese 68 year old male E4 carrier with mild AD and type 2 
diabetes showed promise (329). The patient was screened at baseline via the Montreal 
Cognitive Assessment (MoCA) test and comprehensive diabetic and lipid tests. The patient 
was prescribed a ketogenic diet over a 10-week period with intermittent fasting on an 8 
hour time-restricted feeding window for 3 days per week. The patient showed remarkable 
improvement from baseline in HgA1c levels (from diabetic to normal range), fasting 
insulin (85% reduction), body weight (5.5% reduction), and HDL levels (35.7% 
improvement). Furthermore, MoCA revealed an improvement in cognition with the patient 
scoring in the mild-AD range at baseline (23/30) and normative range post-intervention 
(29/30). While this is only a case report (n=1), the study begs the question; are the 
metabolic derangements driven by E4 mitigated by simply restricting feeding? Future 
studies are needed in APOE mice models and humans to address this fundamental gap in 
our knowledge.  
The metabolism hypothesis of AD states that the primary pathogenic driver of 
disease progression is altered brain metabolism (330). This hypothesis is supported by a 
number of studies that reflect AD-associated impairments in mitochondrial respiration and 
aberrant upregulation of glycolysis. For example, fibroblasts taken from LOAD patients 
show inherent decreased glucose oxidation, diminished mitochondrial membrane potential, 
increased oxidative stress, and a Warburg-type effect that is unrelated to the age of the 
patient (331, 332). Recent proteomic profiling of over 2000 AD brain samples revealed 
that changes in expression of proteins involved in glial metabolism is the most significant 
module associated with AD pathology and cognitive decline (118). Increased expression 
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of enzymes in this module included lactate dehydrogenase, pyruvate kinase, and 
glyceraldehyde-3-phosphate dehydrogenase, all of which are elevated in aerobic 
glycolysis/Warburg phenotypes. Laser microdissection of neurons from the posterior 
cingulate of AD postmortem samples has revealed reduced expression of electron transport 
genes (333). AD-related reduction in  ETC activity may also explain findings from Terada 
and colleagues who used a novel FDG probe that binds to mitochondrial complex 1 to show 
oxidative metabolic failure in parahippocampal regions of living early stage AD brains 
(334). As stated previously, AD brains show lower FDG PET uptake and this is considered 
one of the earliest biomarkers of disease (328, 335). FDG-PET is able to differentiate AD 
from other types of dementia with a high degree of specificity due to specific regional 
signaling patterns.(336) Detectable AD symptoms essentially never occur without lower 
FDG-PET signal, and the degree of FDG-PET signal loss is strongly correlated with the 
severity of clinical symptoms (337-339). Interestingly, analysis of CSF samples from 32 
confirmed AD patients showed a significant correlation between increased CSF lactate and 
reduced glucose uptake (by FDG PET) in parahippocampal areas, the medial prefrontal 
cortex, and the left orbitofrontal cortex. Imaging studies in live AD patients via magnetic 
resonance spectroscopy have shown elevated lactate levels in the posterior 
cingulate/precuneus region compared to controls (340). Elevated brain lactate correlates 
strongly with mild cognitive impairment progression (341), and in a mouse model of AD 
correlates well with interstitial amyloid beta levels.  
Based on the data shown in this dissertation, I believe that E4 may be a causative 
driver of AD based on its effect on metabolic flexibility and subsequent lactate production. 
Specifically, I hypothesize that E4 carriers consuming high-caloric diets have greater risk 
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for developing AD because of the increased flux of glucose through aerobic glycolysis to 
lactate. This lactate then serves to suppress glucose uptake in the brain and drive traditional 
AD pathology through mechanisms yet to be determined. 
5.6 Future studies 
Discovering early biological signs that forecast future disease is critical in primary 
prevention of disease. With the elderly population predicted to increase significantly in the 
coming decades, early detection and intervention will be critical to lower healthcare burden 
in the treatment and care of AD patients. Young female E4 carriers offer a unique sample 
population as being at high risk for development of late onset AD, yet with no age-related 
AD symptomology. Similar to the seminal finding that young E4 carriers show FDG-PET 
imaging congruent with AD patients (3), we show here that young female E4 carriers show 
a resting energy expenditure profile congruent with aged individuals. It is unclear if whole 
body energy expenditure is altered in AD (342) and future studies aiming to validate 
indirect calorimetry as a screen for AD risk should confirm EE alterations in the AD 
population.  
5.7 Conclusion 
In summary, I have shown that APOE regulates fatty acid metabolism in astrocytes, 
whole body response to glucose challenges in humans and mice, and central carbon 
pathways in mice brains and astrocytes. These data show the metabolic effects of E4 in the 
central nervous system but also show peripheral mechanisms for APOE regulation of 
metabolism. While questions remain, these findings inform the field of neurometabolism 







5.8 APPENDIX 1 – CHAPTER 2 SUPPLEMENTARY MATERIALS 
Supplementary Table 1 – Ratios of plasma metabolite abundances in human participants 
with or without the E4 allele. 




Metabolite HMDB ID Ratio FDR Ratio FDR 
beta-alanine HMDB0000056 1.059 0.797 1.179 0.314 
cholesterol HMDB0000067 1.176 0.541 1.084 0.699 
citrate HMDB0000094 1.258 0.273 1.276 0.152 
GABA HMDB0000112 1.203 0.532 1.419 0.096 
glyoxylic acid HMDB0000119 0.822 0.489 0.891 0.542 
glycine HMDB0000123 1.102 0.717 1.098 0.546 
glycerol 3-phosphate HMDB0000126 1.002 0.994 0.853 0.542 
fumaric acid HMDB0000134 0.940 0.797 0.822 0.314 
glyceric acid HMDB0000139 1.243 0.193 1.310 0.034 
glutamic acid HMDB0000148 1.427 0.066 1.757 0.011 
ethanolamine HMDB0000149 1.141 0.532 1.160 0.291 
tyrosine HMDB0000158 1.072 0.797 1.331 0.153 
phenylalanine HMDB0000159 0.999 0.994 1.141 0.354 
maltose HMDB0000163 1.143 0.775 1.681 0.028 
threonine HMDB0000167 0.597 0.107 0.897 0.546 
isoleucine HMDB0000172 1.063 0.798 1.183 0.299 
lysine HMDB0000182 0.929 0.797 1.197 0.216 
lactose HMDB0000186 1.218 0.466 1.471 0.057 
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serine HMDB0000187 1.025 0.919 1.277 0.118 
lactate HMDB0000190 1.519 0.001 1.264 0.013 
oleic acid HMDB0000207 0.722 0.294 0.991 0.957 
α-ketoglutarate HMDB0000208 1.084 0.775 1.057 0.715 
myo-inositol HMDB0000211 1.149 0.532 1.508 0.028 
n-acetylgalactosamine HMDB0000212 1.507 0.054 1.359 0.275 
palmitic acid (polar lipids) HMDB0000220 1.074 0.797 1.341 0.098 
n-acetyl-neuraminic acid HMDB0000230 1.026 0.919 1.676 0.013 
pyruvate HMDB0000243 1.128 0.532 1.108 0.464 
sucrose HMDB0000258 0.817 0.649 0.791 0.326 
serotonin HMDB0000259 0.757 0.242 1.032 0.861 
pyroglutamic acid HMDB0000267 1.256 0.312 1.336 0.153 
ribose HMDB0000283 0.9659 0.894 1.102 0.546 
urea HMDB0000294 1.1415 0.621 1.117 0.441 
creatinine HMDB0000562 0.7535 0.445 0.701 0.098 
fructose HMDB0000660 1.212 0.489 1.429 0.028 
linoleic acid polar HMDB0000673 0.914 0.797 1.066 0.750 
methionine HMDB0000696 1.268 0.358 1.205 0.313 
homoserine HMDB0000719 0.857 0.647 0.688 0.098 
malic acid HMDB0000744 1.185 0.441 1.185 0.247 
3-phosphoglyceric acid HMDB0000807 1.306 0.0843 1.398 0.018 
stearic acid HMDB0000827 1.156 0.532 1.317 0.143 
valine HMDB0000883 1.174 0.533 1.217 0.284 
tryptophan HMDB0000929 0.957 0.822 1.105 0.54 
threonic acid HMDB0000943 1.464 0.065 1.977 0.0013 
F16BP HMDB0001058 0.783 0.242 0.927 0.584 
glucosamine-1-phosphate HMDB0001109 0.739 0.193 0.883 0.527 
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alanine  HMDB0001310 1.018 0.919 1.192 0.244 
guanosine-5-phosphate HMDB0001397 1.063 0.797 0.848 0.353 
glucosamine HMDB0001514 1.531 0.066 1.724 0.002 
oxalic acid HMDB0002329 1.024 0.919 0.929 0.715 
threose HMDB0002649 0.772 0.414 1.043 0.772 
n-acetyl-tryptophan HMDB0013713 1.076 0.797 1.220 0.354 
acetohydroxamic acid  HMDB0014691 1.186 0.532 1.187 0.353 
aspartyl-glutamate HMDB0028752 0.581 0.162 0.576 0.096 





















Supplementary Table 2. Pre-screening checklist.  A response of “yes” to any of the 
following resulted in exclusion from the study. 
 
 
   Pre-Existing Symptoms Checklist 
INSTRUCTIONS: Review this list at each 
visit. If any symptom is present at Baseline, 




Symptom Yes No Comments 
1. pregnant or breastfeeding Yes No  
2. have a bleeding disorder Yes No  
3. allergy to the local anesthetic lidocaine Yes No  
4. history of stroke, seizures, Parkinson’s 
disease, history of head injury with loss of 
consciousness, or other dementing disorder 
Yes No  
5. history of alcoholism or drug abuse Yes No  
6. History of schizophrenia or currently 
suffer from bipolar disorder or major 
depression. 
Yes No  
7. vision or hearing loss severe enough to 
interfere with cognitive testing 
Yes No  
8. Taking Beta Blockers (ex. Sectral, 
Tenormin, Zebeta, Lopressor, Corgard, 
Bystolic, Inderal LA, InnoPran XL) 
Yes No  
9. Taking Neuroleptics (ex. Clozaril, 
Saphris, Zeprexa, Seroquel) 
Yes No  
10. Taking Narcotic Analgesics (ex. 
Codeine, Zohydro ER, Oxycodone, 
Methadone, Hydromorphone, Morphine, 
Fentanyl) 
Yes No  
11. Taking Anti-Parkinsonian Agents (ex. 
Sinemet, Symmetrel, Artane, Cogentin, 
Elderpryl, Azliect, Comtan) 
Yes No  
12. Taking CNS-Active antihypertensive 
agents (ex. Catapres, Kapvay, Intuniv, 
Tenex) 
Yes No  




Fig. S1. Human indirect calorimetry study design  
(A) Representative time course of energy expenditure (EE) measures during the three 
periods of the study (rest in gray, cognitive challenge in green, and glucose challenge in 
orange). Data was only analyzed during the last 25 minutes of the resting and glucose 
periods and during a common 5-15 minute span during the cognitive challenge in which 
all 100 subjects were actively engaged in the task – denoted by grey bar on x axis. Blood 
was drawn immediately prior and after the glucose challenge. (B) Representative photo 
of a participant during the resting challenge connected to the Ultima MGX indirect 
calorimetry (IC) system. (C) Example slides from the Novel Image Novel Location test 
used as a cognitive challenge. (D) The glucose challenge consisted of a blood draw, 
followed by ingestion of the 50g sugar drink (all subjects consumed drink within 90 


















Fig. S2. Respiratory Exchange Ratio (RER) does not differ by APOE genotype. 
  Respiratory exchange ratio (RER) (VCO2/VO2) was not significantly different 








Fig. S3. E4 effect on resting energy expenditure  
(A) E4 non-carriers’ (blue) and E4 carriers’ (purple) average resting energy expenditures 
were determined and stratified by young and middle-aged. (*P<0.05, ***P<0.001, 
unpaired t-test, two-tailed)(B) This was repeated for only male participants (*P<0.05, 
unpaired t-test, two-tailed). (C) Average EE was plotted over the resting period for 







Fig. S4. Novel image novel location object recognition test response accuracy by 
APOE genotype.  
(A) The novel-image-novel-location (NINL) object recognition test contains 7 sets of 
12 slides. Each slide has 3 images and 4 possible locations. Each slide is viewed for 
eight seconds in the order as follows: See Set A, See Set B. Test Set A, See Set C, Test 
Set B, See Set D, Test Set C, etc. To be considered correct, subjects must identify both 
the type of change and in which quadrant the change has occurred. The test is designed 
so that on average subjects answer 60-80% of questions correctly. Total percent correct 
was calculated for each genotype (B) and stratified by E4 carriage. (C) Individual slopes 






Fig. S5. E4 effect on energy expenditure during glucose challenge  
(A) Energy expenditure (B) VCO2 and (C) VO2 was plotted over the glucose challenge 
period in all E4- (blue) and E4+ (purple) participants. (*P<0.05, Two-way ANOVA 
repeated measures). (D) Thermic effect of feeding was determined as a ratio of E4 non-
carriers in all, young, and middle-aged participants. (**P<0.01, unpaired t-test, two-
tailed) (E) Energy expenditure (F) VCO2 and (G) VO2 was plotted over the glucose 
challenge period in male participants. Dotted lines show linear regression trend line, 
shaded areas refer to SEM. (H) Thermic effect of feeding was determined as a ratio of 
































Fig. S6. Plasma lactate assessed via enzymatic assay.  
(A) Lactate values quantified by GCMS (relative abundance, y-axis) strongly correlate 
with lactate values (uM) assessed via enzymatic assay. (B) E4 carriers had higher plasma 
lactate pre-drink and a trend toward higher lactate post-drink (p=0.09) compared to non-













Fig. S7.  Activity, food consumption, and age comparisons from mice indirect 
calorimetry  
(A) Activity and (B) food consumption during light cycles were averaged for E3 and 
E4 mice. (C) Analysis of covariance was performed by separately correlating average 

















Fig S8. Indirect calorimetry data from male mice  
(A) Normal chow and (B) high carbohydrate data from male mice only corresponding 











    
 
 
Fig S9. Indirect calorimetry data from female mice  
(A) Normal chow and (B) high carbohydrate data from female mice only corresponding 




Supplementary Materials and Methods 
 
Glucose metabolism assays 
For glucose oxidation assays, astrocytes were plated in a 24-well plate at 300,000 
cells/well with 500 µL of maintenance media (Advanced DMEM, 10% FBS, 1% sodium 
pyruvate, 0.4% Geneticin) and incubated at 5% CO2 and 37°C and allowed to grow to 
confluency for 24 hours. Using a previously published protocol (290), cells were then 
incubated with 1 µCi/mL [U-14C] glucose in maintenance media (25mM glucose) or 
starvation media (same as maintenance except 0mM glucose) for 3 hours. Buffered 14CO2 
in the media was then liberated by addition of 1 M perchloric acid and captured on a filter 
paper disc pre-soaked with 1N sodium hydroxide using airtight acidification vials. 
Radioactivity of the filter paper was measured in a Microbeta 2 Scintillation Counter 
(Perkin Elmer) after addition of 3 mL Ultima-Gold Scintillation Fluid.  
For glucose tracing in primary astrocytes, cells were plated in a 6-well plate at 
600,000 cell/well in astrocyte growth media (Advanced DMEM, 10% FBS, 1% sodium 
pyruvate, 1% penicillin-streptomycin) and incubated at 5% CO2 and 37°C. After 48 hours, 
growth media was replaced with tracer media (Glucose-free DMEM containing 10% 
dialyzed FBS, 10mM [U-13C] glucose) and incubated under previous conditions for 24 
hours at which time quenching and metabolite extraction were carried out as follows: Plates 
were retrieved from incubator and placed on ice, tracer media removed and wells washed 
once with ice-cold PBS. Immediately following washing, 1 mL of ice-cold extraction 
buffer (50% MeOH, 20nM norvaline) was added to quench enzymatic activity and plates 
were placed at -20°C for 10 min. Cellular contents were then scraped with a cell-scraper in 
extraction buffer and collected into 1.5 mL and tubes placed on ice for 20 min with regular 
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vortexing. Samples were then centrifuged at 14,000 rpm, 10 min, 4°C after which 
supernatant containing polar metabolites were removed to a new tube and frozen at -80°C 
until prepped for GCMS analysis. The resulting pellet was re-suspended in RIPA buffer 
(Sigma) and protein concentration was measured with BCA kit (Pierce) for normalization.  
 
Glucose tracing in vivo 
Female TR mice homozygous for E3 or Ε4 (12-13 mo) were fasted for 2-3 hours 
then, via oral gavage, administered 250 uL [U-13C] glucose solution at a concentration of 
2 g/kg of body weight based on average cohort bodyweight. 45 minutes following gavage, 
mice were euthanized by cervical dislocation, brains were removed and quickly washed 
twice in PBS, once in H2O then frozen in liquid N2. Tissues were kept at -80°C until ground 
under liquid N2 using a Freezer/Mill Cryogenic Grinder (SPEX SamplePrep model 
9875D). Approximately 60 mg of tissue was placed in a 1.5 mL tube then 1 mL extraction 
buffer (50% MeOH, 20nM norvaline) was added followed by a brief vortex and placed on 
ice for 20 min, briefly vortexed every 5 min. Samples were then centrifuged at 14,000 rpm, 
4°C for 10 min. The supernatant containing polar metabolites was removed to a new tube 
and kept at -80°C until prepped for GCMS. The resulting pellet was re-suspended in RIPA 
buffer (Sigma) and protein concentration was measured with BCA kit (Pierce) for 
normalization. 
 
GCMS Sample Preparation 
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Polar metabolites were thawed on ice then dried under vacuum. Dried pellet 
dissolved in 50 uL methoxyamine HCl-pyridine (20 mg/ml) solution and heated 60 minutes 
at 60°C. Following heating, samples were transferred to v-shaped glass chromatography 
vials and 80 ul of MTSFA + 1% TMCS (Thermo Scientific) was added. Samples then 
heated for 60 minutes at 60°C then allowed to cool to room temperature and analyzed via 
GCMS with parameters as previously described (343). Briefly, a GC temperature gradient 
of 130°C was held for 4 minutes, rising at 6°C/min to 243°C, rising at 60°C/min to 280°C 
and held for two minutes. Electron ionization energy was set to 70 eV. Scan and full scan 
mode used for metabolite analysis, spectra were translated to relative abundance using the 
Automated Mass Spectral Deconvolution and Identification System (AMDIS) software 
with retention time and fragmentation pattern matched to FiehnLib library with a 
confidence score of >80. Chromatograms were quantified using Data Extraction for Stable 
Isotope-labelled metabolites (DExSI) with a primary ion and two or more matching 
qualifying ions. Metabolite quantification was normalized to relative abundance of internal 
standard (L-norvaline), brain and cell data also normalized to protein concentration. 
Metabolomics data was analyzed using the web-based data processing tool Metaboanalyst 
(344). Metabolites significantly altered by APOE genotype and/or time point were defined 
by ANOVA and subsequent false discovery rate cutoff of < 0.05. All identified metabolites 
for which >75% of participants had a measurable concentration were included, and missing 
values were estimated with an optimized random forest method (345). For the pathway 
impact analysis, the parameters were set to ‘global test’ and ‘Relative-betweenness 
Centrality’, a node centrality measure which reflects metabolic pathway ‘hub’ importance. 
For enrichment analyses, parameters were set to “Pathway-associated metabolite sets 
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(SMPDB)”, a library that contains 99 metabolite sets based on normal human metabolism. 
For both pathway and impact analyses, only metabolic pathways with 3+ metabolites 
represented in our data set were included, and a false discovery rate cutoff of <0.05 was 
utilized.   
 
Mitochondrial respiration assays 
Astrocytes were plated at 40,000 cells/well in maintenance media and grown to 
confluency for 24 hours. The following day media was replaced with assay running media 
(Seahorse XF Base Medium, 1mM pyruvate, 2mM glutamine, and 10mM glucose) and 
after 1 hour oxygen Consumption rate (OCR) and extracellular acidification rate (ECAR) 
were measured using a Seahorse 96XF instrument as previously described 
(126). Manufacturer protocols were followed for the glycolysis stress test assay and Mito 
fuel flex assay. Briefly, the glycolysis stress test assesses the ability of cells to respond to 
challenging conditions by increase the rate of glycolytic activity. Glycolytic capacity refers 
to the glycolytic response to energetic demand from stress (Glycolytic capacity = ECAR 
post-oligomycin – Baseline ECAR) while glycolytic reserve refers to the capacity available 
to utilize glycolysis beyond the basal rate (Glycolytic reserve = ECAR post-oligomycin – 
ECAR post-glucose). The Mito Fuel Flex assay assesses mitochondrial energy 
consumption by measuring respiration in the presence or absence of fuel pathway 
inhibitors. The following equations were used in the calculations of mitochondrial 
flexibility parameters: Dependency (%) = [(Baseline OCR - Target inhibitor OCR)/ 
(Baseline OCR - All inhibitors of OCR)] x 100%. Capacity (%) = 1 / [(Baseline OCR - 
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Other two inhibitors of OCR)/(Baseline OCR - All inhibitors of OCR)] x 100%. Flexibility 


























Supplementary Figure 1  - E4 astrocytes express more perilipin-2 
E3 and E4 astrocytes were incubated in Advanced DMEM with or without 250 µM oleic 
acid (OA) conjugated to BSA. Protein was extracted by RIPA lysis and 20µg was loaded 





Supplementary Figure 2 -  E4 astrocytes secrete less ApoE into the media and have less 
intracellular ApoE 
(A) Media and cell lysates from E3 and E4 astrocyte cell cultures were isolated. Samples 
were assayed for ApoE using Abcam Human ApoE ELISA kit as previously described 
(346). (B) E3 and E4 cell lysates were separated using SDS-PAGE and immunoblotted 








Supplementary Figure 3 – E4 astrocytes form more lipid droplets 
(A) E3 and E4 expressing astrocytes were lipid loaded for 24 hours in control or oleic acid 
supplemented media. Cells were fixed and incubated with oil red O to stain lipid droplets. 
(B) Oil red O stained LDs were quantified using image J. Values represent means +/- SEM 
from 8 images. Data was analyzed by t-test. **p<0.005 
         
 





Oil Red O Histology 
Oil Red O staining was performed as previously described (346). Astrocytes were plated 
on TissueTek chamber slides. After lipid incubation, media was aspirated and slides were 
washed 2X with sterile PBS. 4% PFA was added for 30 min at 37 C to fix the cells, 
followed by a PBS wash. 60% isopropanol was added to the chamber wells for 5 min for 
permeabilization. Isopropanol was aspirated and the cells were dried. Oil red O was then 
added to the chamber wells for 20 min followed by 3 washes in ddH2O. Chambers were 
removed from the slides and then coverslips were mounted. Images were acquired at 100X 
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